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Abstract 
The demand for long-term home health care services for the aged (≥65 years) is growing. 
Aged people needing home care (HC) are increasingly older, have many chronic diseases 
and use multiple medicines, and thus, are at a high risk for drug-related problems (DRPs). 
Practical nurses (PNs) are those who most often visit the aged using HC services and 
consequently, are in a key position to monitor the expected positive outcomes and risks of 
pharmacotherapy of their clients.  
The aim of this study was to develop and validate an easy-to-use DRP Risk Assessment 
Tool (DRP-RAT) for PNs caring for home-dwelling aged ≥65 years focusing on identifying 
and solving the highest priority DRP risks. The specific aims were: 1) to systematically 
review articles that describe criteria for assessing inappropriate prescribing in the aged ≥65 
years; 2) to describe the development process and content validation of the DRP-RAT; 3) 
to evaluate the feasibility of the final DRP-RAT among PNs in HC; and 4) to assess the 
reliability of risk assessments conducted by PNs by using DRP-RAT and to identify the 
clinically most significant DRPs needing action. 
This study applied both quantitative and qualitative methods. Original English language 
articles were systematically searched on MEDLINE and PubMed, with a time restriction of 
1.1.1990–17.6.2010, focusing on the development methods and contents of the criteria for 
potentially inappropriate prescribing for the aged (Study I, year 2010). Two systematic 
literature reviews (Study I, an unpublished one) and the expertise of the research group were 
used as a basis for the development of the DRP-RAT. The content of the draft tool was 
validated by a three-round Delphi survey with a panel of 18 experts in geriatric care and 
pharmacotherapy (Study II, year 2010). Data for the feasibility study were collected during 
the training of PNs, working in HC, in the use of the DRP-RAT (Study III, year 2011). For 
Study III, an analysis was made of the PN-conducted (n=25) DRP risk assessments of their 
self-selected clients by DRP-RAT (n=85) and the same clients’ copied medication lists 
(n=68), face-to-face discussions and responses to open questions of the returned feedback 
forms (n=23). In 2013, an experienced geriatrician reviewed HC clients’ (n=45) medications 
by using three different reviewing methods on each patient (Study IV, year 2013). The 
methods based on: 1) DRP-RAT (n=45) completed by the PNs (n=26) and copied 
medication lists; 2) health centre’s medical records (“gold standard”); and 3) Methods 1 and 
2 together. Results of the reviews and contents of the geriatrician’s open comments 
regarding the PNsʼ risk assessments were analyzed. DRPs in the study population identified 
and reported by the geriatrician were studied from the geriatrician’s DRP classifications 
(n=45) and by a retrospective review of the geriatrician’s case reports (n=45). 
Most of the criteria were explicit (10 out of 14), consensus validated, based totally or 
partly on Beers criteria, and focused on pharmacological appropriateness of prescribing. 
The majority represented a quantification of misprescribing, e.g., potentially inappropriate 
medications, most common harmful drug-drug and drug-disease interactions and related 
potential geriatric-specific adverse effects. The final DRP-RAT consisted of 18 items that 
 
 
 
 
assess risks for DRPs in home-dwelling clients. It is divided into four sections: 1) Basic 
Client Data, 2) Potential Risks for DRPs in Medication Use, 3) Characteristics of the 
Clientʼs Care and Adherence and, 4) Recommendations for Actions to Resolve DRPs. PNs 
spent on average 20±8 minutes reviewing one client’s medication using the DRP-RAT and 
reliably identified 88% of the risk medicines used by their clients listed in the tool. Of the 
respondents (n=23) of the feedback forms, 43% reported it was easy or quite easy to answer 
the questions of the DRP-RAT. Generic names of medicines, time constraints, home-care 
workers’ and/or clients’ lack of interest to clients’ pharmacotherapy and short client contacts 
were the most common barriers to using the tool. The DRP-RAT completed by the PNs was 
capable of providing reliable and timely patient information to support physician’s clinical 
decision making. Compared to the “gold standard” (Method 2), Method 1 resulted in a false 
negative rating in 7% (95 % CI 1.4–18.3) of the cases (3/45). The geriatrician identified an 
average of 3.1 potential DRPs per patient.  
This study indicates that the DRP-RAT, developed and validated in this study, could 
make it possible to more effectively involve PNs, working in HC, in medication risk 
management among the home-dwelling aged, and that medication risk management should 
be focused on the highest priority risks. Unlike existing nurse-administered risk assessment 
tools focusing mainly on issues relating to adherence and medication management, the 
DRP-RAT focuses on the highest priority risks related to the pharmacological effects of the 
medications but also on factors related to the medication use process. Integrating training to 
use the DRP-RAT into PN curricula is important. Actions to facilitate the implementation 
of the DRP-RAT in the Finnish health care system are needed. Future studies are needed to 
evaluate the effects of PNsʼ risk assessments using the DRP-RAT on clinical, humanistic 
and economic outcomes.  
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Definitions of the key concepts 
Adverse drug event (ADE) 
Any injury occurring during the patient’s medicine therapy and resulting either from 
appropriate care or from unsuitable or suboptimal care. Includes adverse drug reactions 
during normal use of medicine, and any harm secondary to a medication error, both errors 
of omission or commission (Council of Europe 2006a). 
 
Adverse drug reaction (ADR)  
A response to a medical product which is noxious and unintended, and occurs at doses 
normally used in man (Council of Europe 2006a). 
 
Adverse event (AE) 
An unintended injury caused by medical management rather than by a disease process 
(Council of Europe 2006a). 
 
Culture of safety 
An integrated pattern of individual and organizational behavior, based upon shared beliefs 
and values, that continuously seeks to minimize patient harm which may result from the 
processes of care delivery (Council of Europe 2006a). 
 
Deprescribing 
Tapering, reducing or stopping a medication (Farrell et al. 2015). 
 
Drug-Related Problem (DRP) 
Originally defined as “An undesirable patient experience that involves drug therapy and that 
actually or potentially interferes with a desired patient outcome” (Strand et al. 1990). 
Currently widely used definition for DRP is “An event or circumstance involving drug 
therapy that actually or potentially interferes with desired health outcomes (PCNE 2010). 
Often used as a synonym of the term “drug-therapy problem” defined as “any undesirable 
event experienced by the patient that involves or is suspected to involve drug therapy and 
that actually or potentially interferes with desired health outcomes (Cipolle et al. 1998, 
2004). In this thesis, DRPs are discussed (if not otherwise mentioned) on the basis of the 
definition of the PCNE 2010 (PCNE 2010). 
 
Cause (process) of a drug-related problem  
The process leading to a drug-related problem can be understood as a failure associated with 
the process of medicine use (Basger et al. 2014). It can also be defined as an action (or lack 
of action) that leads to the occurrence of a potential or real problem (PCNE 2010). There 
may be more than one causes for each problem. Medication errors may be named as causes 
of DRPs (PCNE 2010), or medication errors can be causes of risks to DRPs (Council of 
Europe 2006a). 
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Geriatric pharmacotherapy  
Tailored pharmacotherapy for the aged taking into account aged-related body changes that 
affect how medicines are handled. Most often used age-limits are: ≥65 years or ≥75 years 
(AGS 2015, Finnish Medicines Agency 2015a). 
 
Home care  
In Finland a Health Centre is a primary care unit and part of the public health care system, 
which is the dominating health care system covering the entire population through public social 
insurance (Teperi et al. 2009). Health centres offer a wide variety of services, including home 
care. Municipal home care services encompass social and health services including home 
help and home nursing.  Home care services for the aged are nearly always provided as long-
term services. In this thesis, when discussing home care it is preferred to term home nursing.  
 
Inappropriate prescribing 
A situation in which the pharmacotherapy does not meet accepted medical standards 
(Hanlon et al. 2001). 
 
Medication adherence 
The extent to which a person’s behaviour in taking medicines corresponds with the agreed 
recommendations from a health care provider (WHO 2003). 
 
Medication error 
Any preventable event that may cause or lead to inappropriate medication use or patient 
harm while the medication is under the control of the health care professional, patient, or 
consumer. Such events may be related to professional practice, health care products, 
procedures, and systems, including prescribing; order communication; product labelling, 
packaging, and nomenclature; compounding; dispensing; distribution; administration; 
education; monitoring; and use (NCC MERP 2016). 
 
Medication review 
A structured evaluation of patient‘s medicines with the aim of optimizing medicine use and 
improving health outcomes. This entails detecting drug-related problems and recommending 
interventions (PCNE 2016a). Medication review procedures may differ in comprehensiveness 
and in the levels of multiprofessional collaboration (Clyne et al. 2008, Leikola 2012). 
 
Medication safety 
Medication safety refers to quality and safety of pharmacotherapy. Medication safety 
comprises both adverse drug reactions (product safety) and medication errors (safety of 
health-care services) (STAKES and ROHTO 2006). Defined also as freedom from accidental 
injury during the course of medication use; activities to avoid, prevent, or correct adverse 
drug events which may result from the use of medicines (Council of Europe 2006a). 
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Medication use system  
A combination of interdependent processes that share the common goal of safe, effective, 
appropriate, and efficient provision of medicine therapy to patients. Major processes in the 
medication use system are: selecting and procuring; storage; prescribing; transcribing and 
verifying/reviewing; preparing and dispensing; administering and monitoring (Council of 
Europe 2006a). 
 
Patient safety 
Patient safety is the prevention of errors and adverse effects to patients associated with 
health care (WHO 2016). Also defined as the identification, analysis and management of 
patient-related risks and incidents, in order to make patient care safer and minimize harm to 
patients (Council of Europe 2006a). 
 
Potentially inappropriate medication (PIM) 
In this thesis, the term potentially inappropriate medication refers to medication that is 
considered to be inappropriate for individuals aged 65 years and older. It is considered as 
inappropriate because of questionable efficacy, unfavorable benefit-risk or because safer 
alternatives exist (Beers et al. 1991, Fick et al. 2003, AGS 2015).  
 
Practical nurse 
Health care professional having three years vocational education that concentrates mainly 
on supporting and technical nursing (Finnish National Board of Education 2010). 
 
Risk assessment 
The process that helps organizations understand the range or risks that they face both 
internally and externally, the level of ability to control those risks, the likelihood of 
occurrence and their potential impacts. It involves a mixture of quantifying risks and using 
judgement, assessing and balancing risks and benefits and weighing them for example 
against cost (Council of Europe 2006a). 
 
Risk management 
Clinical and administrative activities undertaken to identify, evaluate, and reduce the risk 
of injury to patients, staff, and visitors and the risk of loss to the organization itself (Council 
of Europe 2006a). 
 
System 
A set of interdependent elements interacting to achieve a common aim. These elements may 
be both human and non-human (equipment, technologies) (Council of Europe 2006a). 
 
Systems approach  
A system-based approach presupposes the systematic design of safe structures, procedures 
and processes, together with corrective reactions in response to safety incidents. It is 
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accepted that errors are a consequence of normal human fallibility and/or deficiencies of the 
system; these could be prevented by improving the conditions in which humans work. The 
aim is a system designed with built-in defences (Council of Europe 2006b). 
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Abbreviations 
AACP  Australian Association of Consultant Pharmacy 
ADE              Adverse Drug Event 
ADR Adverse Drug Reaction 
ADD Automated Dose Dispensing 
AFP Association of Finnish Pharmacies 
AGS American Geriatric Society 
AOU Assessment of Underutilization of Medication 
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DUR Drug Utilization Review (USA) 
GheOP3S  Ghent Older Peopleʼs Prescriptions community Pharmacy Screening Tool 
Tool 
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GP General Practitioner 
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IPET Improving Prescribing in the Elderly Tool 
MAI Medication Appropriateness Index  
MR Medication Reconciliation 
MRAQ Medication Risk Assessment Questionnaire 
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MUR Medication Use Review (England, Wales) 
NCC MERP National Coordinating Council for Medication Error Reporting and 
                      Prevention (US) 
NORGEP Norwegian General Practice 
NSAID Non-steroidal anti-inflammatory drug 
OTC Over-The-Counter 
PCNE Pharmaceutical Care Network Europe 
PIM Potentially Inappropriate Medication 
PN Practical Nurse 
PPI Proton Pump Inhibitor 
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PREVENT Physical impairment, Risk from specific med/medicines related admission, 
adhErence issues, cognitiVe impairment, nEw diagnosis/exacerbation of 
disease, compliaNce, socieTal/social – Risk Indicator for Medicines-related 
Problems 
RCT Randomized Controlled Trial 
RMMR Residential Medication Management Review (Australia) 
ROHTO National Centre for Pharmacotherapy Development 
SFINX Swedish, Finnish, INteraction X-referencing 
SII Social Insurance Institution of Finland 
SMA Tool Swedish Safe Medication Assessment Tool 
SSRI Selective Serotonin Reuptake Inhibitor 
STAKES National Research and Development Centre for Welfare and Health 
START Screening Tool to Alert doctors to Right Treatment  
STOPP Screening Tool of Older Personʼs Prescriptions  
TIPPA Tarkoituksenmukainen Informaatio Potilaan Parhaaksi Apteekista: 
Customized Information for the Benefit of the Patient from the Community 
Pharmacy  
WHO World Health Organization 
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1 Introduction 
Medication risk management has become an increasingly more important area of research 
during the last decades. This is because medication use has become more common, leading 
to complex medications particularly among the aged. According to the Act on Supporting 
the Functional Capacity of the Older Population and on Social and Health Care Services for 
Older Persons (980/2012) an “older person” is “a person whose physical, cognitive, mental 
or social functional capacity is impaired due to illnesses or injuries that have begun, 
increased or worsened with high age or due to degeneration related to high age”. From the 
pharmacological approach aged people can be considered as “a special population” differing 
from younger adults in terms of comorbidity, polypharmacy, pharmacokinetics and 
pharmacodynamics. Due to age-related body changes and other factors related to aging (e.g., 
memory problems, impaired hearing and/or vision, impaired cognition) older people as 
medicine users are vulnerable to a wide range of drug-related problems which makes 
prescribing for the aged challenging. 
Drug-related problem (DRP) can be defined as “an event or circumstance involving drug 
therapy that actually or potentially interferes with desired health outcomes" (PCNE 2010). 
Terms drug-therapy problem (DTP) (Cipolle et al. 2004) and medication-related problem 
(MRP) (APhA and NACDS Foundation 2008) are often used as synonyms to DRP. Of the 
single type of DRPs adverse-drug reactions (ADRs) are among the most common to result 
in severe harm (Pirmohamed et al. 2004, Patel et al. 2007, van der Hooft et al. 2008, Pedrós 
et al. 2016). A recent systematic review showed that in primary care, patient safety incidents 
resulting in severe harm were most often related to diagnosis and prescribing, and typically 
occurred among the aged or those taking multiple medications (Panesar et al. 2015). 
It is estimated that over a half of the harmful medication incidents could be prevented 
with more active and systematic risk management during the entire medication use process 
(Panesar et al. 2015). This has resulted in a need to develop and implement methods for 
identifying and solving, but also preventing, DRPs. As the medication safety risks are found 
to cumulate with older medicine users (Panesar et al. 2015) a growing number of risk 
management methods are specifically designed for the aged.  
The focus of this doctoral thesis is the development and validation of a Drug-Related 
Problem Risk Assessment Tool (DRP-RAT) for use by practical nurses (PNs) taking care 
of home-dwelling clients ≥65 years, with the aim of involving PNs working with aged home 
care clients in medication risk management. The literature review of this thesis (Chapters 
2–3) aims to provide a conceptual and theoretical background for the empirical research. 
International and national strategies and tools to prevent and resolve DRPs in geriatric 
pharmacotherapy are introduced in Chapters 4 and 5. Chapter 6 represents an overview of 
Finnish studies which aim to identify and resolve problems related to medicine use of the 
aged. 
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2 Drug-related problems 
The concept “inappropriate use of medicines” comprises several different improper ways to 
use medicines, which potentially lead to DRPs (Figure 1). 
 
 
 
Figure 1 Drug-related problems can occur for many reasons during the medication use 
process (STAKES and ROHTO 2006) 
Through time, researchers have tried to understand factors leading to inappropriate use 
of medicines, potential problems resulting from inappropriate medicine use and their 
prevention. This has resulted in the development of standardized DRP classification 
systems, the first of which was the Strand classification developed in the US by Strand and 
colleagues (Figure 2, Table 1) (Strand et al. 1990, Basger et al. 2014). The Strand 
classification was an essential part of the philosophy of pharmaceutical care launched by 
Charles Hepler and Linda Strand from the University of Florida in 1990 (Hepler and Strand 
1990). The core element of the philosophy and practice of pharmaceutical care is to identify, 
solve and prevent DRPs in cooperation with a patient and other health care professionals. 
According to this philosophy, in addition to dispensing medicines, pharmacists are also 
responsible for monitoring medicine treatments and evaluating their outcomes. The 
philosophy extends quality assurance principles and systems thinking to clinical 
pharmacotherapy in patient care and emphasizes the integration of drug therapy with other 
elements of care. 
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The aim of this Chapter is to describe milestones in the development of DRP 
classification systems since 1990 when the first classification system was launched (Strand 
et al. 1990, Figure 2). 
 
 
Figure 2 Milestones in development of DRP classification systems since 1990 when the first 
classification system was launched by Hepler and Strand (Hepler and Strand 1990) 
US
•Strand et al. 1990 
•8 categories of DRPs 
•For use by pharmacists 
in community 
pharmacies to change 
the focus of practice 
from products to 
ensuring the best drug 
therapy and patient 
safety
•Revisions:
•Cipolle et al. 1998 and 
2004 (identical)
•7 problem categories
•33 cause categories
•Cipolle et al. 2012
•7 problem categories
•37 cause categories
•For use in multiple 
health care settings
EUROPE
•PCNE classification
•Versions V1 (1999) -
V6 (14.1.2010)
•various number of 
primary problem and 
cause categories and 
subcategories based on 
the version
•PCNE V6.2 (current 
version) (PCNE 2010)
•4 primary problem 
categories with 11 
subcategories
•8 primary cause 
categories with 35 
subcategories
•4 intervention 
categories with 18 
subcategories
•4 outcome categories 
with 7 subcategories
•For international use in 
multiple health care 
settings
AUSTRALIA
•Aggregated classification 
system for causes of DRPs 
(Basger et al. 2015)
•Constructed from contents of 
7 DRP classification systems:
•Cipolle et al. 1998 and 2004 
(identical systems), 
•Cipolle et al. 2012
•The DOCUMENT system 
(Williams et al. 2012)
•The individualized 
Medication Assessment and 
planning (iMap) tool (Crisp 
et al. 2011)
•The Norwegian system 
(Ruths et al. 2007)
•PCNE classification V6.2
(PCNE 2010)
•The Westerlund system 
version 5 (Westerlund 2009)
•2 problem categories
•9 primary cause categories 
with 33 subcategories and 58 
sub-subcategories
•For universal use in multiple 
health care settings
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2.1 Drug-related problem (DRP) classification systems 
Since the launch of the Strand’s DRP classification in 1990 (Strand et al. 1990, Hepler and 
Strand 1990), researchers in different countries have developed several classification 
systems for DRPs and their causes (Basger et al. 2014, Figure 2). These systems differ e.g., 
in definitions of DRPs; a recent systematic literature review by Basger and colleagues 
(2014) identified altogether twelve definitions of DRPs, the majority mixing both process 
of drug use (or cause) and outcome (or problem). This has resulted in differences in the 
number and contents of problem and cause categories. For example, the problem identified 
in the PCNE Classification V6.2 “The patient suffers from an ADR at normal dose or from 
a toxic reaction” is the same as the sub-cause “An adverse drug reaction occurred” in 
Basgerʼs classification of causes of DRPs (PCNE 2010, Basger et al. 2015).  
Over time, the classifications have moved towards integrating causes of DRPs as an 
essential part of the classification system (Figure 2), indicating the importance of 
understanding causes for building up safer medication use processes and preventing DRPs 
to occur. This is in line with the current systems thinking in patient safety in which 
deficiencies in medication safety have been prioritized as the most important single factor 
jeopardizing patient safety (Council of Europe 2006a). The classifications can be used in 
clinical practice to document the nature, prevalence, and incidence of DRPs, but also as 
process indicators in medication safety research. 
2.1.1 The Strand classification 
The Strand classification was originally developed to enhance pharmacist’s involvement in 
ensuring the optimum drug therapy and patient safety (Figure 2, Table 1) (Strand et al. 
1990). The classification served as an aid in the development of standards of practice for 
pharmacists. Strand and colleagues defined DRP as “an undesirable patient experience that 
involves drug therapy and that actually or potentially interferes with a desired patient 
outcome”. Eight categories of DRPs were identified (Strand et al. 1990, Table 1). Problems 
and causes were not separated in this classification. Later, the classification was revised by 
renaming DRPs as DTPs (Drug-Therapy Problems), also drug interactions were removed 
from problem category to cause category as they were considered as causes for DTPs 
(Cipolle et al. 1998, Cipolle et al. 2004). Thus, the revised classification included 7 problem 
categories and 33 cause categories (Figure 2). The latest revision of the classification 
includes 7 problem categories and 37 cause categories (Cipolle et al. 2012). 
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Table 1. Categories of Drug-related Problems (DRPs) in the original classification system 
by Strand et al. (1990)  
DRP category and definition 
1. Untreated indication 
The patient has a medical condition for that requires drug therapy (a drug indication) 
but the patient is not receiving a drug for that indication 
2. Improper drug selection 
The patient has a medical condition for which the wrong drug is being taken 
3. Subtherapeutic dosage 
The patient has a medical condition for which too little of the correct drug is being 
taken 
4. Overdosage 
The patient has a medical condition for which too much of the correct drug is being 
taken 
5. Adverse drug reaction 
The patient has a medical condition resulting from an adverse drug reaction 
6. Drug-interactions 
The patient has a medical condition resulting from a drug-drug, drug-food, drug-
laboratory interaction 
7. Failure to receive drugs 
The patient has a medical condition that is the result of not receiving the prescribed 
drug 
8. Drug use without indication 
The patient has a medical condition that is the result of taking a drug for which there 
is no valid medical indication 
2.1.2 Pharmaceutical Care Network Europe (PCNE) classification system 
Another landmark in the DRP classification systems is the European PCNE classification 
(PCNE 2010, Figure 2, Table 2). Pharmaceutical Care Network Europe (PCNE) started 
under WHO EuroPharm Forum and was established in 1994 by European pharmaceutical 
care researches (PCNE 1999). PCNE became an independent official association (under 
Dutch law) in 2004. 
Knowing the variability between previous DRP classification systems the development 
of the PCNE classification aimed at a comprehensive standardized system that could be 
used in international studies to ensure comparable results (van Mil et al. 2004a, Figure 2).  
The first PCNE classification system for DRPs was constructed in 1999 during the working 
conference of PCNE (PCNE 1999). Later, the DRP system has been validated and updated 
regularly, the latest version (V6.2) being updated in 2010 with the following DRP definition: 
“A Drug-Related Problem is an event or circumstance involving drug therapy that 
actually or potentially interferes with desired health outcomes" (PCNE 2010). Currently, 
this hierarchical classification lists 4 primary DRP categories: 1) (potential) problems with 
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the (lack of) effect of the pharmacotherapy; 2) patient suffers, or will possibly suffer, from 
an adverse drug event; 3) the drug treatment is more expensive than necessary; or 4) others, 
with altogether 11 subcategories. The classification system also includes 8 primary and 35 
subcategories for causes of DRPs, and 5 primary and 18 subcategories for interventions that 
the problems can lead to in order to correct the cause(s). Furthermore, the system has an 
outcome section to indicate if the problem has been solved. The 5th working symposium of 
PCNE was held in February 2016. Among other matters, the workshop started working on 
version 7.0 of the classification (PCNE 2016b).  
In addition to research purposes DRP classifications are applicable to clinical practice. 
E.g., in Finland, a modified version of the PCNE classification 5.01 and later a slightly 
modified version V6.2 have been used as part of the collaborative comprehensive 
medication review (CMR) procedure which has been in use since 2005 (Leikola et al. 2009, 
Leikola et al. 2012a, Leikola et al. 2012b, Leikola 2012). So far, about 200 pharmacists 
have been accredited to conduct CMRs in Finland (Leikola et al. 2016). 
2.1.3 Recent developments: An aggregated system for classifying causes of 
drug-related problems  
A recent systematic literature review identified 20 different types of DRP classification 
systems and their modifications developed during the last 25 years (Basger et al. 2014 and 
2015). Wide variability between the systems found results in the lack of a comprehensive 
and universally acceptable classification system making study comparisons difficult. 
Noticing this lack Basger and colleagues performed a category-by-category comparison of 
the content of seven selected DRP classification systems (Cipolle et al. 2004, Westerlund 
2009, PCNE 2010, Grisp et al. 2011, Ruths et al. 2011, Williams et al. 2011, Cipolle et al. 
2012) in modified or unmodified form in order to construct an aggregated cause-of-DRP 
classification system containing the content of all systems (Basger et al. 2015, Figure 2). 
The PCNE Classification V6.2 was used as a template for the analysis (Basger et al. 2015). 
Those seven systems were identified after the previous literature review (Basger et al. 2014) 
and were selected based on their use in various health care settings, developing country, 
frequency of use, and development methods (Basger et al. 2014 and 2015). The resulting 
hierarchical system has two categories for actual or potential DRPs: 1) drug treatment goals 
are not reached (i.e., the drug does not work) and 2) drug treatment causes an undesirable 
effect or effects (i.e., the drug causes harm). It encompasses 9 cause-of-DRP categories with 
33 subcategories, and 58 sub-subcategories (Table 2). This new categorization may provide 
the most comprehensive description of causes of DRPs to date. 
Recent classifications have a broad approach to DRPs as they comprehensively identify 
different factors that (potentially) cause negative outcomes related to the whole medicine 
use system. The more detailed the cause categories are the more easy it is to understand that 
the causes potentially leading to DRPs may occur at every step of the medicine use process 
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and may be related to each individual dealing with the patient’s pharmacotherapy as well as 
to medicine.  
Table 2 gathers causes of DRPs listed in the PCNE classification V6.2 (PCNE 2010) 
and in Basger’s aggregated classification system (Basger et al. 2015). They are (re)grouped 
according to factors (patient, carer, nurse, physician, medicine and pharmacist) that they 
may be related to. It is notable that one cause can be related to several factors. According to 
the current understanding and classifications (Basger et al. 2015), the cause of DRP can be 
in prescribing (e.g., selection of the drug, drug form or dosing), in the way in which the 
patient selects or uses the drug or in the way in which it has been administered, in supply 
(e.g., dispensing, drug not available, transferring error), in monitoring (e.g., too frequent or 
too infrequent monitoring, inappropriate test ordered), or an ADR has occurred or there may 
be no obvious reason for treatment failure. 
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3 Factors associated with drug-related problems in the 
aged  
Due to age-related body changes and increasing number of chronic diseases leading to 
polypharmacy, aged people are most vulnerable to DRPs requiring special attention with 
their pharmacotherapy (Mangoni and Jackson 2003, ELDesoky 2007, Hilmer et al. 2007a). 
Although DRP classifications described in the previous chapter are general, not age-
specific, they are particularly valuable in geriatric pharmacotherapy in identifying DRPs 
and understanding their causes (Table 2). The model below (Figure 3) provides an 
illustration of key factors posing a risk to DRPs in the aged. The evidence for the model is 
derived from Table 2 and research described in more detail later in this chapter.  
 
 
 
 
Figure 3 Factors posing risks to DRPs in the aged (based on Table 2 and the articles focusing 
on DRPs in the aged that are discussed below)  
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Polypharmacy
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3.1 Patient-related factors 
3.1.1 Age-related body changes and comorbidities leading to polypharmacy  
Ageing is associated with several physiological changes that affect how medicines work in 
the body and thus, how medicines should be prescribed to older people (Table 3, Mangoni 
and Jackson 2003, ELDesoky 2007). Ageing also leads to impaired homeostasis and wide 
variability in drug response between individuals which makes medicine dosing and 
administration challenging (Hilmer et al. 2007a). The number of chronic diseases increases 
with advanced age leading to complex medications and polypharmacy (Jyrkkä et al. 2009a). 
Polypharmacy, in turn, increases risk of DRPs, such as adverse-drug reactions (ADRs). 
Fulton and Allen (2005) estimated that the risk of ADRs is 13% when using two 
medications, increasing up to 58% when using five medications. When using seven or more 
medications the ADR incidence risk increases to 82% (Prybus 2002). ADRs in the aged can 
be difficult to identify as they may be present as symptoms already prevalent in aged people 
e.g., dizzy spells, falls or confusion (Gaeta et al. 2002). Polypharmacy also increases the 
risk of having medicines classified as inappropriate for the aged (Fialova et al. 2005, Bell 
et al. 2013, Jirón et al. 2016).  
Table 3. Age-related changes and their influence on prescribing and/or medicine use in the 
aged (Mangoni and Jackson 2003, ELDesoky 2007, Hilmer et al. 2007a) 
Physiological changes that can influence  
pharmacokinetics of medicines 
Influence on prescribing 
and/or medicine use 
General 
 
1. Reduced total body mass 
2. Changes in body composition   
 a) decrease in total body water => higher serum 
concentrations for hydrophilic medicines 
 b) increase in proportion of body fat => prolonged 
half time for lipophilic medicines 
 
Increasing risk for adverse-
drug reactions (ADRs) 
 
Sensitivity to orthostatic 
episodes  
 
Increasing need for careful 
monitoring of the patient’s 
response to medicines 
 
Need for dose adjustments 
(decrease) 
 
Certain “high risk” medicines 
should be avoided when 
possible 
 
Gastrointestinal 
tract 
Reduced gastric emptying rate, gastric acid 
production, gut motility, gut blood flow 
Circulation Decreased cardiac output  
Decreased plasma protein binding 
Liver Reduced liver mass and blood flow 
=> reduced first pass metabolism 
Reduced albumin synthesis 
Alterations of hepatic enzymatic functions 
Kidney Reduced glomerular filtration rate 
Reduced tubular function 
Lung Reduced vital capacity 
Physiological changes that can influence the 
pharmacodynamics of medicines 
Changes in 1. receptor density and/or affinity 
                   2. signal transduction mechanism 
Impairment of cellular response in affected organs 
Homeostasis 
Reduced homeostatic reserve 
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3.1.2 Patient-related factors associated with medication nonadherence   
Physiological body changes are not the only patient-related factors posing risks to DRPs in 
aged medicine users. Behavioral aspects, such as negative attitudes towards medicines or 
alternatively non-drug treatments leading to nonadherence, also are important but quite 
often ignored factors leading to DRPs (Table 2, Figure 4). DRP classifications include 
several causes for DRPs that can be related to the way the patient selects or uses the 
medicines, gets the medicines administered, or are otherwise related to the patient’s 
personality or behavior (Table 2, Figure 4, PCNE 2010, Basger et al. 2015). DRPs also may 
occur due to inadequate or wrong information and instructions, miscommunication and/or 
misunderstanding that can cause the patient to take the medicine incorrectly.  
 
Figure 4 Patient-related and medicine-related factors related to nonadherence posing risks to 
DRPs among aged medicine users. The model was constructed on the basis of studies 
by Fuller and Watson (2005), STAKES and ROHTO (2006), Dickinson et al. (2010), 
Doggrell (2010), PCNE (2010) and Basger et al. (2015)  
Medication adherence, defined as “the extent to which a person’s behavior in taking 
medicines corresponds with agreed recommendations from a health care provider” (WHO 
2003), is a key component in managing illnesses (Osterberg et al. 2005). Nonadherence, in 
its turn, has been associated to poorer health outcomes, residential care and hospital 
admissions and re-admissions, and thus, increased health care costs (Gurwitz et al. 2003, 
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Pirmohamed et al. 2004, Doggrell 2010). Nonadherence encompasses several aspects, such 
as (unintentional or intentional) underuse or overuse of medicines, habit use, abuse or 
neglected use of medicines (STAKES and ROHTO 2006, PCNE 2010, Basger et al. 2015). 
The likelihood of nonadherence is increased among the aged with many chronic illnesses 
and polypharmacy. It has been estimated that nonadherence rates among people aged ≥65 
years vary from 40% to 75% (Doggrell 2010). Figure 4 summarizes key factors found to be 
related to medication nonadherence among the aged.  
Reasons for nonadherence include factors related to the medicine (e.g., costs, number of 
medicines, adverse effects) and those related to the person (e.g., impaired cognition, 
impaired vision, depression, negative attitudes, poor economic situation) (Fuller and 
Watson 2005, Dickinson et al. 2010, Doggrell 2010, Figure 4). The study of Fuller and 
Watson (2005) identified that patient’s mental state, attitudes towards and knowledge about 
medicines and visual impairment demonstrated a high risk to safe medicine self-
management. Poor mental state, disinterested attitude towards medicine and living alone 
without help create a very high-risk situation irrespective of the number of prescribed 
medicines. Dickinson and colleagues (2010) investigated attitudes of older patients and their 
GPs to taking long-term antidepressant therapy. The study indicated that patients often 
echoed antipathy to non-drug treatment such as counselling. Related to habit use of 
medicines Dickinson and colleagues (2010) identified several barriers to discontinuation of 
antidepressants following four themes: 1) pessimism about the course and curability of 
chronic depression; 2) negative expectations and experiences related to aging; 3) 
discontinuation perceived by patients as a threat to stability; and 4) passive and active 
decisions to accept the continuing need for medication.  
3.2 Medicine-related factors  
Quite often the same evidence and therapeutic guidelines are applied to prescribing 
medicines to older adults as to “standard adults”. This is due to the fact that there is a lack 
of evidence on the effects and safety of medicines in older adults (European Medicines 
Agency 2006 and 2015). This is the case for most licensed pharmaceutical products, not 
only for newly approved ones. The reason for the limited evidence is that aged people 
(especially those ≥80 years) continue to be under-enrolled in industry-sponsored pre 
approval drug studies or are excluded entirely from clinical trials although they are large 
medicine consumers for a number of chronic diseases (Van Spall et al. 2007, European 
Medicines Agency 2006 and 2015). This makes it difficult to generalize on the benefits and 
risks found in clinical trials for older patients who are typical users of those medicines. Also 
short trial durations and modest sample sizes are inadequate to fully predict actual clinical 
outcomes of newly marketed pharmaceutical products among the aged (European 
Medicines Agency 2006 and 2015, Van Spall et al. 2007, Avorn 2010). The demand for 
involving older adults in clinical trials is increasing (European Medicines Agency 2006 and 
2015).  
However, already today certain medicines and medicine groups are known to be harmful 
for the aged based on research and experience of experts in geriatric care and 
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pharmacotherapy. Based on literature reviews and these expert opinions e.g., 
benzodiazepines, strong anticholinergics and antipsychotics are listed as potentially 
inappropriate medicines (PIMs) for the aged, and should be avoided where possible (AGS 
2015, Finnish Medicines Agency 2015a). Since 1991, several criteria listing medicines 
potentially inappropriate for the aged have been developed in order to manage potential 
risks caused by these medicines (Beers et al. 1991, Fick et al. 2003, AGS 2015, Finnish 
Medicines Agency 2015a). However, although not being recognized as PIMs all medicines 
can cause undesirable reactions (e.g., allergic reactions) that are not dose-related and may 
occur at a normal therapeutic dose.  
Generic substitution, i.e., once a patent has expired, a medicine is sold under a generic 
name (International Nonproprietary Name (INNs)) as a substitute for the original brand-
name medicine, is a risk factor for medication errors (Schwab et al. 2002, Håkonsen et al. 
2011, Lobo et al. 2013). Using both trade and generic names of medicines may lead to 
confusion and subsequently to overdosing and also may influence in adherence (Schwab et 
al. 2002, Colombo et al. 2016).    
3.3 Health care staff related factors  
3.3.1 Prescriber 
Several factors relating to prescribing may cause DRPs among the aged (Table 2, PCNE 
2010, Basger et al. 2015). Inappropriate drug selection e.g., selection of “high risk drugs”, 
contraindicated drugs, inappropriate combination of drugs, or drugs and food, or drugs and 
alcohol, may represent causes for DRPs. Some indications may not be treated and via versa 
some medicines may be prescribed without indication. Drug form, treatment duration or 
dose selection may be inappropriate, also issues related to logistics (e.g., a drug order does 
not meet legislative requirements) may represent risk to DRPs.  
Although several prevalence studies in several countries indicate that inappropriate 
prescribing among the aged is common both in outpatient and inpatient care (Panesar et al. 
2015), less attention has been paid to why it happens and how it can be prevented. A recent 
meta-synthesis (i.e., a qualitative synthesis) of Cullinan and colleagues (2014) offers a novel 
approach to understanding why it happens from the prescriber’s point of view. The meta-
synthesis base on a literature search of English language studies that use qualitative methods 
and explore some area of potentially inappropriate prescribing among patients 65 years and 
over (Cullinan et al. 2014). A systematic search from PubMed, Embase, CINAHL and Web 
of Knowledge databases up to the end of April 2013 (no start day was specified) produced 
7 articles (Damestoy et al. 1999, Spinewine et al. 2005, Cook et al. 2007, Agarwal et al. 
2008, Wood-Mitchell et al. 2008, Dickinson et al. 2010, Spitz et al. 2011). Most of those 
articles (71%) handled prescribing of CNS medications i.e., psychotropics, 
benzodiazepines, antidepressants and opioids (Damestoy et al. 1999, Cook et al. 2007, 
Wood-Mitchell et al. 2008, Dickinson et al. 2010, Spitz et al. 2011). Results of the meta-
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synthesis indicated that physicians often have self-perceived restrictions leading to a sense 
of powerlessness to prescribe appropriately (Cullinan et al. 2014). The study found four key 
concepts being causal factors in inappropriate prescribing: 1) the need to please the patient; 
2) a feeling of being forced to prescribe; 3) tension between prescribing experience and 
prescribing guidelines and 4) prescriber fear. These thematic concepts are described in more 
detail below.  
3.3.1.1 The need to please the patient  
Although a patient-centered approach to pharmacotherapy has been highlighted, at times, 
the patient may have too much of a deciding role in his/her therapy. This may complicate 
the physician’s decision making and prevent actions that would objectively be best for the 
patient (Cullinan et al. 2014). Cook et al. (2007) explored practicing primary care 
physicians’ attitudes to prescribing benzodiazepines for older adults. None of the physicians 
considered benzodiazepines use among the aged to be a priority clinical or public health 
problem. They saw no cases of addiction in their aged patients and focused a little 
recognition to adverse effects other than addiction, which they saw as the main concern of 
benzodiazepine use and discontinuation. They thought that the continuation of 
benzodiazepine use is compassionate and discontinuation harsh. They found it quicker and 
easier to prescribe what the patient wants than spend time persuading patients that a different 
approach to managing insomnia or anxiety would be preferable. They also expressed 
pessimism in successful tapering or discontinuation in aged patients with long-term use of 
benzodiazepines and referred to prior failed attempts. Dickinson et al. (2010) found that 
both GPs and their patients found discontinuation of long-term use of antidepressants as a 
threat to stability; they did not want to “rock the boat”. The possibility of the patient’s 
switching to another physician was also identified as a reason for inappropriate prescribing 
(Damestoy et al. 1999, Cook et al. 2007). Damestoy and colleagues (1999) described how 
patients, previously described as fragile and vulnerable, became demanding and difficult 
when their use of anxiolytics was questioned.  
3.3.1.2 Feeling forced to prescribe  
In addition to the need to please the patient there also were other situations, where the 
physicians felt that they were forced to prescribe, or not prescribe although they realized it 
was not appropriate (Cullinan et al. 2014). Wood-Mitchell et al. (2008) found that 
psychiatrists (working in inpatient clinics and in community-care settings) felt pressured to 
prescribe psychotropics for behavioral and psychological symptoms of dementia due to 
resource issues (e.g., differences in the level of care between care homes) and lack of 
availability of alternative treatments. Also the study of Dickinson and colleagues (2010) 
found that one frequently cited reason for favouring antidepressants by GPs working in 
primary care trusts was inadequacy or unavailability of alternative treatments. Some 
physicians realized an inappropriate use of certain medicines to be a public health problem 
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but they felt it was beyond the scope of an individual physician (Damestoy et al. 1999, Cook 
et al. 2006). In a study of Agarwal and colleagues (2008) GPs described situations where 
their experience of the lack of knowledge in particular nursing homes or less-than ideal care 
situations, hindered them from considering insulin treatment.  
3.3.1.3 Experience vs. guidelines  
According to the meta-synthesis of Cullinan et al. (2014) the prescribers were aware of the 
potentially inappropriate nature of some of their prescribing and mostly were aware of the 
treatment guidelines and agreed with them. However, they felt that it was difficult to 
implement the guidelines in practice and the end result was reversion to previous practices 
which they were familiar with. Lack of evidence supporting some guidelines also influenced 
the prescribers in favour of their own experiences (Wood-Mitchell et al. 2008). As the 
physicians did not often see the adverse effects there was little concern about those (Cook 
et al. 2008, Dickinson et al. 2010).  
3.3.1.4 Prescriber fear 
Feeling a sense of fear in prescribing to older patients due to frailty and co-morbidities (fear 
of causing harm) were reported by physicians (Spinewine et al. 2005, Argwall et al. 2008). 
In a study of Spitz et al. (2011) the physicians described the fear of prescribing opioids for 
older patients because of the worry regarding several adverse effects. The physicians also 
reported that they did not want to stop certain medications because of the fear of disrupting 
patients’ clinical stability (Dickinson et al. 2010). The physicians also reported a fear of 
offending other doctors, including specialists and GPs (Spinewine et al. 2005). E.g., when 
the physician noticed something potentially inappropriate, but it was prescribed by a 
specialist, it was not likely they intervened, or the patient transfer information between 
levels of care could be limited by fear of offending the prescribed physician with comments 
of inappropriate prescribing.  
3.3.1.5 Interventions to promote appropriate prescribing 
Results of the meta-synthesis indicate that methods for empowering physicians to prescribe 
appropriately should be developed (Cullinan et al. 2014). Educational interventions, such 
as pre- and postgraduate education about geriatric pharmacotherapy, improving “non-
technical skills” such as communication skills, team-working, leadership and risk-managing 
skills could also be possible methods. At the systems level ways to improve communication 
between levels of care should be further developed and resources for geriatric care should 
be increased.  
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3.3.2 Nurses and pharmacists  
Errors in the drug use process (administration, dosing), in logistics (administering a drug 
from the wrong patient’s drug chart), inappropriate monitoring or incorrect or inadequate 
patient counselling are among factors that may cause DRPs related to both nurses and 
pharmacists (Table 2, PCNE 2010, Basger et al. 2015). In addition to the above mentioned, 
dispensing errors may cause DRPs related to pharmacists.  
3.4 System-related factors  
Several of the above mentioned risk factors could be managed by improving the health care 
system, which is a challenge that requires attention in national level and should be priority 
in health policy making (Airaksinen et al. 2012). Competence and curriculum development, 
improving data systems in and between health care units, improving conditions under which 
people work (e.g., adequate guidance on processes) and assuring accessibility and quality 
of medicines information both for the health care staff and the patients are among the 
important issues that should be focused on related to a systems approach to medication 
safety.  
3.4.1 Competence and curriculum development  
3.4.1.1 Geriatric pharmacotherapy  
Inappropriate prescribing (e.g., selection of wrong or inappropriate medicine, errors in 
dosage regimen), administration errors, inadequate or incorrect patient counselling and 
inadequate follow-up evaluation may result from health care professionals’ lack of 
knowledge in geriatric pharmacotherapy. Several studies indicate that there are deficiencies 
in geriatric pharmacotherapy skills among health care professionals (Kivelä 2006, Avorn 
2010, Cullinan et al. 2014). Thus, curriculum redesign and adequate continuing education, 
focusing more on geriatric pharmacotherapy, should be key components in improving 
educational programs for all health care professionals (physicians, nurses, pharmacists).  
3.4.1.2 Interprofessional co-operation  
Inadequate or incorrect information transfer between different health care professionals may 
also lead to medication errors. Information may also be misunderstood. In order to learn 
working together and discussing “the same language” interprofessional co-operation should 
be emphasized and trained already during basic education (WHO 2010). In practice, actions 
aiming to influence attitudes and traditional norms within health care institutions should be 
done in order to support interprofessional co-operation (Kallio 2014). 
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3.4.2 Data systems  
Errors in information transfer when patients are transferred between different levels of care 
(e.g., from hospital to long-term care) or between different health care units may cause 
DRPs (Crotty et al. 2004, PCNE 2010, Basger et al. 2015). Lack of uniform patient data 
registering practices by all health care professionals may also cause errors. Thus, several 
demands concerning the data systems also exist. Compatible data systems between different 
health care units, in order to assure continuous and reliable information transfer, should be 
guaranteed (Ministry of Social Affairs and Health 2011a). Health care professionals’ 
technical skills to ensure reliable use of the software programs should be assured. Systems 
supporting rational prescribing practices should be further developed and introduced. Tools 
developed to improve medication safety should be actively distributed and further 
developed for use throughout the whole pharmacotherapy process and for all professionals 
dealing with the pharmacotherapy of the aged.  
3.4.3 Guidance on processes within health care institutions  
Health care institutions should be supported to develop plans and procedures to improve 
medication safety (Ministry of Social Affairs and Health 2011a). Disease specific care 
pathways, unit based and individual pharmacotherapy plans are among the most important 
actions as well as naming a person in charge for each patient.  
3.4.4 Medicines information and empowerment  
Inadequate and/or unreliable medicines information provided to health care professionals or 
to the patients may result in pharmacotherapy risks (Finnish Medicines Agency 2012, 
Hämeen-Anttila et al. 2012 and 2013). Especially, in regard to the aged medicine users 
actions focusing on increasing readability and understandability of the information should 
be emphasized. Patient empowerment and involvement in their own care have been focused 
on as key components in improving medication safety (Ministry of Social Affairs and Health 
2011a). Not only the patients but also the health care professionals should be empowered to 
appropriate pharmacotherapy of the aged (Cullinan et al. 2014).  
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4 Risk management in geriatric pharmacotherapy 
4.1 Systems approach to risk management  
A landmark article on general principles of risk management was published by James 
Reason in 2000. Reason’s (2000) principle of human error changed the ideology in risk 
management from an individual to a systems level. Reason viewed the problem of human 
error in two ways “persons approach” and “systems approach”. The persons approach 
focuses on individual errors, such as forgetfulness or inattention. The systems approach 
concentrates on the conditions under which people work, and tries to build defenses to avert 
errors or mitigate their effects. Reason (2000) introduced the “Swiss Cheese” model to 
illustrate the idea of managing the risks of organizational accidents (Figure 5). This systems 
approach encompasses successive layers of defence, barriers and safeguards in the process 
in order to prevent single individuals making mistakes.  
 
 
 
Figure 5 Human error - The Swiss Cheese Model illustrating risk management from systems 
approach (Reason 2000) 
4.1.1 Extending the Swiss Cheese Model to managing risks in 
pharmacotherapy 
The “Swiss Cheese” model has been widely used to illustrate the systems approach to 
patient and medication safety (Council of Europe 2006a and b, WHO 2011). Medication 
errors may be named as causes of DRPs (PCNE 2010) or, medication errors can be the cause 
 
 
 
 
44 
of risks to DRPs (Council of Europe 2006a). Among the most discussed  preventitive actions 
for medication errors and consequently DRPs have been different types of medication 
reviews (Leikola 2012, Bulajeva et al. 2014, Kiiski et al. 2016), medication counselling, 
multidose dispensing/automated dose dispensing (Sinnemäki et al. 2013 and 2014), manual 
and electronic risk assessment tools, and other collaborative and coordinated practices 
involving  pharmacists as part of the team (Kivelä 2006, Ministry of Social Affairs and 
Health 2007, Finnish Medicines Agency 2016). Figure 6 shows a modification of Reason’s 
(2000) Swiss Cheese Model that illustrates how  interprofessional collaboration can be 
coordinated to assist in risk management of  pharmacotherapies at different levels of care 
involving patients and healthcare providers with the available skills and tools that each of 
them have (Modified from Chen et al. 2006). 
 
 
 
Figure 6 Modification of Reason’s (2000) Swiss Cheese Model to illustrate interprofessional 
approach to DRP risk management in pharmacotherapy (Modified from Chen et al. 
2006) (DRP=drug-related problem, GP=general practitioner, PN=practical nurse)  
Another modification of Reason’s Swiss Cheese Model illustrates how collaborative 
medication reviews can be used as a preventive action for medication errors (Figure 7, Chen 
et al. 2006). In that model, the medication process covers also the manufacturer and 
regulatory authority which assures that pharmaceutical products are effective and safe. 
Medication reviews are planned to cover the medication use part of the process, including, 
e.g., prescribing, dispensing and monitoring.   
The Swiss Cheese Model  
Coordinated DRP risk assessment at different levels of care taking into 
account each actor’s clinical skills and available risk assessment tools 
      DRP 
     
 
 
 
 
 
Specialist GP Pharma-
cist 
Nurse PN Patient 
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Figure 7 Another modification of Reason’s (2000) Swiss Cheese Model to illustrate how 
collaborative medication reviews can be used as a preventive action to medication 
errors in healthcare (Chen et al. 2006) (GP=general practitioner)  
4.1.2 Hepler and Strand’s pharmaceutical care philosophy in operationalizing 
Reason’s human error theory in medication risk management  
 
Hepler and Strand’s pharmaceutical care philosophy (Hepler and Strand 1990) assists in 
operationalizing Reason’s (2000) general human error theory in medication risk 
management. As Figures 6 and 7 show, DRPs and collaborative medication reviews, 
concepts introduced by Hepler and Strand in medication management, fit well to the idea of 
medication risk management providing concrete tools for identifying, solving and 
preventing DRPs. Other medication-specific procedures and tools can similarly be regarded 
as system-based preventive actions to improve medication safety. The philosophy of 
pharmaceutical care and efforts to implement it in different countries throughout the world 
since 1990s has brought community and hospital pharmacists more involved in medication 
risk management in healthcare (Berenguer et al. 2004, van Mil et al. 2004b, Besangon 2010, 
Harris et al. 2014).  
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4.2 DRP risk management tools  
Medication reviews at different levels have been recognized as fundamental in medication 
risk management (National Health Service Act 2006, APhA and NACDS Foundation 2008, 
Pharmaceutical Society of Australia 2011a and b, Leikola et al. 2012a, PCNE 2016a). This 
has led to the need to develop tools for identifying risk patients needing medication reviews. 
The first screening tool for medication risks was developed by Koecheler et al. in 1989. The 
tool consisted of six medication risk predicting indicators. It was designed for use by 
pharmacists, when reviewing patient charts in ambulatory care clinics, to screen patients 
that may have problems in their medication (Koecheler et al. 1989).  
Later, realizing the fact that due to pharmacokinetic and pharmacodynamic alterations 
and multimorbidity leading to polypharmacy, aged people may, in terms of pharmacology, 
be considered as “a special population” needing geriatric specific screening tools 
(Barenholz Levy 2003, Johnson et al. 2005). In addition to different screening tools, the 
need for tools to identify potentially inappropriate prescribing among the aged became 
evident. The first prescribing guidelines were published by Dr. Mark Beers MD, a 
geriatrician from the US who developed prescribing guidelines for nursing homes, the so 
called Beers criteria (Beers et al. 1991). The DRP classifications described in Chapter 2 are 
useful in documenting DRPs and their causes identified during medication reviews. Figure 
8 illustrates how different risk management tools can be integrated in a medication review 
process targeted at the aged. Essential tools in risk management in geriatric 
pharmacotherapy are discussed in this Chapter. 
 
 
Figure 8 Illustration of how different kinds of risk management tools can be integrated in a 
medication review process  
Medication 
review 
Geriatric-specific 
screening tools to 
screen aged 
patients having or 
being at risk for 
DRPs 
Tools measuring 
inappropriate 
prescribing among the 
aged  
DRP 
classifications 
Patient selection 
a) Patient selection 
b) Use during reviews 
Medication 
reconciliation 
The gathered structured 
information can be used  
1) in development of new tools 
2) in updating existing tools 
3) to improve medication use 
processes 
4) to convince the stakeholders 
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4.2.1 Medication review procedures  
In order to ensure safe and rational medication use several medication review procedures 
have been developed worldwide over the last decades. The first procedures originate from 
the US, where prospective Drug Utilization Reviews (pDUR) were mandated since 1993 
after the passage of the Omnibus Budget Reconciliation Act of 1990 (OBRA ʼ90) (Lyles et 
al. 2001, Fulda et al. 2004, Bulajeva et al. 2014). DURs have evolved into Medication 
Therapy Management (MTM) procedures in the US, the development being coordinated by 
AphA and National Association of Chain Drug Stores Foundation (APhA and NACDS 
Foundation 2008). In addition to the US, Australia and the United Kingdom have been 
forerunners in the development of medication review procedures, those also being the first 
countries in incorporating the medication review services into primary outpatient care 
(Lyles et al. 2001, Fulda et al. 2004, Leikola 2012). According to the online survey in 2010, 
medication review procedures are becoming common also in healthcare throughout Europe 
(Bulajeva et al. 2014). Almost two thirds (64%; 16/25) of the European countries which 
responded in 2010 indicated having at least one type of medication review procedure in their 
country.  
Definitions of the term “medication review” differ as well as the medication review 
procedures created in different countries (Clyne et al. 2008, APhA and NACDS Foundation 
2008, Leikola 2012, Bulajeva et al. 2014, AACP 2016, PCNE 2016a, Table 4). Medication 
reviews can be retrospective or prospective (Lyles et al. 2001, Fulda et al. 2004, Clyne et 
al. 2008, Figure 9). Prospective reviews like prospective DUR (pDUR) in the US assess the 
appropriateness of pharmacotherapy at patient level during dispensing e.g., drug-drug 
interactions, drug-disease contraindications (Fulda et al. 2004). Retrospective reviews occur 
after the medicines have been dispensed and the reviews take into account the patient’s 
whole medical history and depending on the review’s comprehensiveness also system 
related factors (Clyne et al. 2008, APhA and NACDS Foundation 2008, Leikola 2012, 
AACP 2016, PCNE 2016a). In collaborative medication review procedures the pharmacist’s 
role is essential in identifying DRPs and solving them jointly with physicians, nurses, 
patients and others involved in the care of each individual patient (Leikola 2012, AACP 
2016).  
The medication review procedures may also differ in the setting (hospital vs primary 
care) where they are conducted. E.g., in Australia medication review procedures have been 
developed both for inpatient settings (Residential Medication Management Review 
(RMMR)) and for community-dwellers (Home Medicines Review (HMR), also known as 
Domiciliary Medication Management Review (DMMR)) (Pharmaceutical Society of 
Australia 2011a and b, AACP 2016). The procedures may differ also in comprehensiveness 
(prescription review, adherence and compliance review, clinical medication review) and in 
the levels of multiprofessional collaboration (Clyne et al. 2008, APhA and NACDS 
Foundation 2008, Leikola 2012, Bulajeva et al. 2014, AACP 2016) RMMR and HMR 
(DMMR) in Australia are comprehensive assessments of patient’s medication conducted by 
pharmacists in collaboration with the GP (Pharmaceutical Society of Australia 2011a and 
b, AACP 2016), while Medication Use Review (MUR) in the UK can be classified as an 
adherence and compliance review where the pharmacist contacts the physician if needed 
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(Clyne et al. 2008). The medication therapy review (MTR) procedure in US is flexible 
allowing comprehensive or targeted reviews depending on the needs of the patient (APhA 
and NACDS Foundation 2008). The procedures may also be developed for special patient 
groups, e.g., the Finnish CMR procedure is especially designed for geriatric patients 
(Leikola 2012). In addition to the above mentioned differences the study of Bulajeva et al. 
(2014) reported differences in access to clinical patient information, documentation forms 
available, quality control and competence requirements (Bulajeva et al. 2014). The 
procedures may be local or national. 
Table 4. Examples of different definitions of medication review procedures  
Country/Area Review Definition 
Europe PCNE  A structured evaluation of patient’s medicines with the aim of 
optimizing medicines use and improving health outcomes. This 
entails detecting drug-related problems and recommending 
interventions (PCNE 2016a) 
Finland CMR A medication review procedure applied nationally in Finland 
and requiring accreditation training for pharmacists conducting 
it. The procedure is based on collaboration between pharmacists 
and other health care professionals, particularly physicians, and 
includes access to clinical patient data, a home visit with a 
patient interview, a comprehensive clinical review of all used 
medication, case conference with the physician and an extensive 
documentation to support the process (Leikola 2012) 
United 
Kingdom 
MUR A structured, critical examination of a patient’s medicines with 
the objective of reaching an agreement with the patient about 
treatment, optimizing the impact of medicines, minimizing the 
number of medication-related problems and reducing waste 
(Clyne et al. 2008) 
Australia HMR 
(DMMR) 
 
 
A Home Medicines Review (HMR) (also known as Domiciliary 
Medication Management Review (DMMR)) involves the 
patient, their general practitioner (GP), an accredited pharmacist 
and regular community pharmacy. In some cases, other relevant 
members of the healthcare team, such as nurses in community 
practice or carers, are included. The pharmacist visits the patient 
at their home, reviews their medicine routine and provides their 
GP with a report. The GP and patient then agree on a medicine 
management plan (AACP 2016) 
RMMR A Residential Medication Management Review (RMMR) is a 
service provided to a permanent resident of an Australian 
Government funded aged care facility (ACF). This includes 
those in flexible care arrangements (transitional care facilities), 
who are not eligible for a Home Medicines Review (HMR) 
(AACP 2016) 
United States MTM The medication therapy review (MTM) is a systematic process 
of collecting patient-specific information, assessing medication 
therapies to identify medication-related problems, developing a 
prioritized list of medication-related problems, and creating a 
plan to resolve them (APhA and NACDS Foundation 2008) 
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Figure 9 Different types of medication reviews constructed on the basis of Lyles et al. 2001, 
Fulda et al. 2004 and Clyne et al. 2008 
4.2.1.1 Implementing medication reviews in health care systems and setting up 
criteria for patient selection  
Medicines are used in different ways in different care pathways and in different care 
settings. Therefore, identification of the points of care where medication reviews are likely 
to be beneficial is crucial. Likewise, the comprehensiveness of the procedure needs careful 
consideration in the selection phase. The most time consuming and expensive of the 
procedures are comprehensive medication reviews. Thus, patients undergoing this type of 
procedure need to be carefully selected. In countries where medication reviews are 
integrated in the health system (e.g., Australia: HMR (DMMR), RMMR; United States: 
MTM; , The United Kingdom: MUR) inclusion criteria for patient selection have been 
developed (APhA 2008, Pharmaceutical Society of Australia 2011a and b, Royal 
Pharmaceutical Society 2016, Table 5). The CMR procedure developed in Finland 
recommends for the patient selection that there is a potential DRP or risk for DRP identified 
by the patient, nurse or pharmacist and the physician has confirmed that the patient may 
benefit from CMR in order to recognize and solve DRPs (Leikola 2012). Further research 
is still needed in setting up evidence-based criteria for patient selection for medication 
reviews and deciding the comprehensiveness of the review required to detect and solve 
DRPs. 
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4.2.2 Medication reconciliation 
Poor communication of medical information when patients are transferred between different 
levels and points of care may cause medication errors resulting in adverse drug events 
(ADEs) (Crotty et al. 2004, Gleason et al. 2010). Medication reconciliation (MR) is a 
process of identifying the most accurate list of the medicines a patient is taking (name, 
dosage, frequency, and route) (Council of Europe 2006a). Reconciliation involves 
comparing the patient’s current medication list with the physician’s admission, transfer, 
and/or discharge orders. Use of this list promotes continuity of treatment between different 
levels and points of care. According to a recent systematic literature review, MR in 
hospitals, community settings and residential age care facilities has the potential to identify 
several medication discrepancies and reduce potential harm (Lehnbom et al. 2014). 
However, there is limited evidence that MR significantly improves clinical outcomes such 
as reductions in hospital admissions. 
4.2.3 Inventory of Tools designed to screen patients at risk for or having 
DRPs  
As the aim of this thesis was to develop and validate a DRP risk assessment tool for use by 
practical nurses taking care of home-dwelling clients ≥65 years, an inventory of existing 
DRP risk assessment tools was conducted. Although this Chapter focuses especially on 
geriatric-specific screening tools designed to be used in outpatient care, also the other tools 
found in the search are briefly discussed. The following aspects of the geriatric-specific 
tools are studied: target group, contents of the tools, in which circumstances and by whom 
the tools are intended to be administered.  
Of the 11 screening tools found (Koecheler et al. 1998, Isaksen et al. 1999, Barenholz 
Levy 2003, Fuller and Watson 2005, Johnson et al. 2005, Langford et al. 2006, Pit et al. 
2007, Hedström et al. 2009, Barnett et al. 2011, Gushdal et al. 2011, Pammett et al. 2015) 
six are geriatric-specific (Barenholz Levy 2003, Fuller and Watson 2005, Johnson et al. 
2005, Pit et al. 2007, Hedström et al. 2009, Gushdal et al. 2011, Table 6). The first screening 
tools were developed in the United States (Koecheler et al. 1989, Isaksen et al. 1999, 
Barenholz-Levy 2003), followed by a tool developed in Canada several years later 
(Langford et al. 2006). Of the found 11 screening tools six (55%) are based mainly or partly 
on Koechelersʼ six risk predicting indicators (Figure 10). Generally, these tools are easy and 
fast to use, and thus, are suitable to be used by various health care professionals or by 
patients themselves in several circumstances.  
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Figure 10 Screening tools derived from Koechelerʼs six indicators 
4.2.3.1 Koecheler’s six risk predicting indicators  
 
To my knowledge, the first screening tool developed to identify patients at risk for, or having 
DRPs was published by Koecheler and colleagues in 1989 (Koecheler et al. 1989) (Figure 
10). The tool was general, not age-specific and designed to be used by pharmacists when 
reviewing patients’ medication charts in ambulatory care clinics. It encompasses six 
indicators to identify ambulatory care patients who may benefit from pharmacists 
monitoring their medications: 1) five or more medications in present drug regimen; 2) 12 or 
more medication doses per day; 3) medication regimen changed four or more times during 
the past 12 months; 4) more than three concurrent disease states present; 5) history of 
noncompliance; and 6) presence of drugs that require therapeutic monitoring. Koecheler’s 
tool is based on existing literature at the time of its development and expert panel opinions. 
The absence or presence of the final six indicators and their adverse outcomes were 
determined through a review of medication charts of 239 patients who visited internal 
medicine, general surgery, pediatric, and obstetric/gynecology clinics during five randomly 
selected weeks in 1985 and 1986. The results found that all six indicators were statistically 
significantly associated with increased risks for adverse outcomes, noncompliance being 
the strongest indicator.  
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4.2.3.2 Screening tools derived from Koecheler’s risk predicting indicators  
A year after Koecheler and colleagues published their risk predicting indicators Isaksen and 
colleagues (1999) published an article describing validation of a computer program 
developed to identify patients at risk for DRPs. The program was developed as a part of 
“The Impact of Managed Pharmaceutical care on Resource utilization and outcomes in 
Veterans Affairs Medical Centre” (IMPROVE) study (Carter et al. 1998). In this study the 
indicators of Koecheler and colleagues (1989) were automated using a computer program. 
Koecheler’s indicators were also utilized as a basis of a screening tool of Barenholz Levy 
(Barenholz Levy 2003). This was the first geriatric-specific screening tool developed 
specially for use in ambulatory aged people and that could be self-administered by the 
patients to identify who is at a high risk for DRPs. The tool encompasses 10 risk predicting 
items (Table 6). Three years later in Canada, Langford and colleagues (2006) modified the 
questionnaire of Barenholz Levy to be used among all adult patients. The modified version 
of the questionnaire of Barenholz Levy (2003) was used in a randomized controlled study 
in order to determine whether a self-administered questionnaire improved identification of 
patients at risk for DRPs compared to standard care (Langford et al. 2006). The use of the 
risk assessment questionnaire led to a 3-fold higher patient referral to pharmacist-led drug 
therapy review than the standard care.  
Koecheler’s six indicators were also used by Australian researchers (Johnson et al. 2005) 
when they developed and tested a set of criteria to screen aged people at high risk for 
untoward medication events in community nursing caseloads focusing on adherence. Four 
predictors of complexity of medication and nonadherence were identified (Table 6, Figure 
10).  
Recently in Canada, studies of Koecheler (1998), Barenholz Levy (2003) and Langford 
(2006) were used to develop a self-administered screening questionnaire (Medication Risk 
Assessment Questionnaire, MRAQ) to be used in community pharmacies in order to 
identify patients having a large number of DRPs (Pammett et al. 2015, Figure 10). The tool 
has five risk predicting questions targeted for all adult patients. 
4.2.3.3 Tools independent of Koecheler’s indicators  
In 2005, Fuller and Watson in the United Kingdom published an article about validation of 
a Self-medication Risk Assessment Instrument (Fuller and Watson 2005). The tool 
measures issues related to adherence, compliance and medication management (see Table 
6). It was designed for older people living alone and was intended to be used by various 
health care workers (acute and community nurses, social service cares, pharmacists, GPs, 
and community therapists). It encompasses seven criteria that are based on evidence-based 
data relating to potential difficulties that individuals may have in managing their 
medications (Table 6). A score rating from 1 to 4 is allocated to each of the seven criteria 
to be assessed. Mental state, attitude and knowledge about medications and severe visual 
impairment demonstrated a high level of validity.  
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Another tool designed to screen aged people with unsafe medication management is a 
Swedish Safe Medication Assessment (SMA) tool (Gusdal et al. 2011, Table 6). The tool 
was developed on the basis of two successive working group recommendations for better 
use of medicines reports in Sweden (Gusdal et al. 2011). The tool is designed to be used by 
HC district nurses (DNs) and it highlights problems with adherence, concordance and 
medication management.  
In order to describe the prevalence of risk factors for medication misadventures among 
older people in general practice in Australia a Medication Assessment Form was developed 
by Pit et al. in 2008 (Table 6). The form encompasses 31 items and was developed based on 
research evidence and expert opinions (Table 6). It was intended to be completed by patients 
themselves in the surgery while waiting for their physician’s appointment. The main 
components of the form are: 1) awareness of the number of medicines used; 2) compliance 
issues; 3) problematic medicine classes; 4) adverse drug reactions; and 5) a recommendation 
section. The most common risk factors identified in the study of Pit and colleagues (2008) 
were: using any medicine longer than 6 months; having more than one doctor involved in 
care; having three or more health problems; or using more than five medicines. A 
subsequent study of Pit et al. (2007) indicated that the Medication Risk Assessment Form 
completed by the patients can be used to select patients for medication review.  
A Swedish study produced and validated an instrument (PHASE-20) for the assessment 
of possible therapeutic drug-related symptoms among the aged (Hedström et al. 2009, Table 
6). The instrument is based on seven pre-existing instruments (Hedström et al. 2009), which 
were coordinated and analyzed for content validity. PHASE-20 was tested in a randomized 
controlled trial among aged people living in nursing homes before and after the review of 
their medicines (Hedström et al. 2009). It encompasses 20 potential symptoms that may be 
related to medication (Table 6). The original version was intended to be used in nursing 
homes where a nurse or a carer assists the resident in completing the tool (Landstinget I 
Uppsala Län, 2014a). Later, a version to be used in outpatient care with instructions for the 
patient on how to complete the instrument was developed (Landstinget I Uppsala Län, 
2014b). Also a PHASE-proxy version exists (Landstinget I Uppsala Län, 2014c). In 2010, 
The Swedish National Board of Health and Welfare recommended the use of the instrument 
(Landstinget I Uppsala Län, 2014d). Currently, it is used in most county councils in Sweden 
in connection with medication reviews.    
In the UK, Barnett and colleagues (2011) developed a PREVENT tool (Physical 
impairment, Risk from spesific med/medicines related admission, adhErence issues, 
cognitiVe impairment, nEw diagnosis/exacerbation of disease, compliaNce, 
socieTal/social). The tool is intended to be used by pharmacists when visiting patients on 
admission to wards. The PREVENT tool supports identification of those patients who have 
unmanaged complex pharmaceutical issues and thus, are at increased risk of preventable 
medication-related readmissions and where the risk can be managed through pharmaceutical 
care (Barnett et al. 2011). Existing published tools, evidence from literature, action research 
and expert opinions were used as a basis for the tool.   
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4.2.3.4 Summary of geriatric specific screening tools  
Altogether six geriatric specific screening tools for use in outpatient care were found 
(Barenholz levy 2003, Fuller and Watson 2005, Johnson et al. 2005, Pit et al. 2007, 
Hedström et al. 2009, Gusdal et al. 2011). Only the Australian screening tool (Pit et al. 2007) 
assessed risks of DRPs during the entire medication use process (Table 6).  The tool of 
Barenholz Levy (2003) also is quite comprehensive but ignores e.g., symptoms suggestive 
of adverse drug reactions and the patient’s social circumstances. Three of the tools (Fuller 
and Watson 2005, Johnson et al. 2005, Gushdal et al. 2011) concentrated on issues related 
to adherence, compliance and medication management. The Swedish Hedströmʼs tool 
(2009) assessed only symptoms suggestive of adverse drug reactions, and thus, had no 
preventive point of view to DRPs. Number of the used medicines, changes in the medicines 
regimen during the past 12 months, more than one physician involved in patients care and 
issues related to non-adherence were the most often identified risks for DRPs. Two of the 
tools were designed to be completed by the patients themselves (Barenholz Levy 2003, Pit 
et al. 2007), Hedstömʼs tool has versions for the patients, nurses and proxies (Hedström et 
al. 2009), others are designed to be completed by nurses (Johnson et al. 2005, Gusdal et al. 
2011) or various health care professionals (Fuller and Watson 2005).  
4.2.4 Criteria measuring inappropriate prescribing among the aged  
Inappropriate prescribing can be defined as a situation in which the pharmacotherapy does 
not meet accepted medical standards (Hanlon et al. 2001). Knowing the fact that 
inappropriate prescribing is common among the aged, different criteria that measure 
inappropriate prescribing have been developed (Spinewine et al. 2007). The criteria can be 
classified as explicit or implicit (Table 7). Some criteria encompass both explicit and 
implicit criteria.  
The US has been the forerunner in developing the criteria. The first explicit criteria were 
developed in 1991 by Mark Beers, MD, a geriatrician from the University of California, Los 
Angeles, as a guideline for nursing homes (Beers et al. 1991). The first implicit criteria 
Medication Appropriateness Index (MAI) was developed also in the US in 1992 by Hanlon 
and colleagues (Hanlon et al. 1992). Due to different selection of marketed drugs in different 
countries the applicability of Beers criteria is limited outside US (Dimitrow et al. 2011). 
Thus in 2008, Gallagher and colleagues developed a European tool called STOPP 
(Screening Tool of Older Personʼs Prescriptions) and START (Screening Tool to Alert 
doctors to the Right Treatment) (Gallagher et al. 2008). This explicit tool encompasses 
criteria measuring both potentially inappropriate prescribing and potential prescribing 
omissions.  
These criteria can be used e.g., as prescribing guidelines, when assessing 
appropriateness of pharmacotherapy of the aged, in educational purposes and in research. 
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Table 7. Characteristics of explicit and implicit criteria  
Explicit Implicit 
Criterion based Clinical judgement based 
Based on existing literature, or existing 
literature and clinical expertise of the 
investigators and/or existing criteria 
Mostly developed in randomized controlled 
trials 
Consensus validated Validated using medical records of the 
participants 
Generally used as rigid standards  Consider patientʼs entire drug regimen 
Drug and/or disease oriented measuring 
pharmacological appropriateness of 
medication 
Can account for patient’s references 
Can be applied with little or no clinical 
patient information 
Rely on user’s expertise 
Uses all available clinical patient 
information 
Time consuming 
Need to be updated regularly  
Country specific Not country specific 
4.2.5 Deprescribing – A novel risk management approach  
4.2.5.1 Evidence-based deprescribing guidelines 
Although, it is well-known that polypharmacy and inappropriate medication use can cause 
DRPs, clinicians still find it difficult to change, reduce or stop medications (Cullinan et al. 
2014).  However, there may be medicines that have positive outcomes at a younger age but 
might be less beneficial or even harmful in the aging patient with several chronic diseases 
or geriatric syndromes (Tinetti et al. 2004). Several tools exist for assessing inappropriate 
medications and for starting needed medications (Spinewine et al. 2007), but no 
systematically developed guidelines have been published to help clinicians safely taper, 
reduce or stop medications which is called deprescribing (Farrell et al. 2015). In 2015, 
Canadian researches published the first priorities for deprescribing for elderly patients 
(Farrell et al. 2015). The article aimed to identify and prioritize medication classes where 
evidence-based deprescribing guidelines would benefit the clinicians. Twenty-nine 
drugs/drug-classes were included in three-round modified Delphi survey, 14 of which 
reached the required level (≥70%) of consensus. The Delphi panel encompassed 65 (the first 
round), 53 (the second round) and 47 (the third round) Canadian geriatric experts 
representing pharmacists, physicians and nurse-practitioners. The final five priorities the 
panelist rated to have an urgent and clear need for a deprescribing guidelines were: 
benzodiazepines, atypical antipsychotics, statins, tricyclic antidepressants, and proton pump 
inhibitors. The protocol for development and implementation of the first three evidence-
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based guidelines for deprescribing in primary care and long-term care setting was published 
by Conklin and colleagues in June 2015 (Conklin et al. 2015).  
4.2.6 Comprehensive Geriatric Assessment (CGA) 
The above described risk management tools are extremely important, however, each of them 
targets only a small part of the whole problem (Budnitz et al. 2011). Comprehensive 
geriatric assessment (CGA) has been seen as “gold standard” of geriatric care as it serves as 
a most comprehensive tool to manage aged peoples’ problems (including medicine use) 
comprehensively (Hickman et al. 2015). CGA is defined as “a multidimensional, 
interdisciplinary diagnostic process to determine the medical, psychological and functional 
capabilities of a frail elderly person in order to develop a coordinated and integrated plan 
for treatment and long-term follow up” (Ellis et al. 2011). This global assessment of aged 
people and their problems allows more specific and sensible care paths for each single 
patient (Schmader et al. 2004). Patient centered medication reviews taking into account co-
existing diseases or geriatric syndromes (e.g., falls, malnutrition, cognitive decline) as part 
of a global assessment of the aged people, are essential in CGA (Onder et al. 2013).  Several 
models for CGAs exist (Hickman et al. 2015). The models may differ in settings they are 
developed for (nursing homes, acute geriatric units, hospitals), in composition of the 
interdisciplinary team (geriatricians, GPs, pharmacists, nurses, physiotherapists, social 
workers) and in clinical assessments conducted.  According to a literature review of Onder 
and colleagues in 2011, compared to former risk management approaches, CGA may result 
in an improvement in the quality of prescribing and in a reduction in the risk of drug-related 
illness (Onder et al. 2011). 
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5 Strategies to prevent and resolve DRPs in geriatric 
pharmacotherapy in Finland  
Since the early 2000s Finland has been actively involved in the European patient and 
medication safety initiatives (Council of Europe 2006a, Council of Europe 2006b). 
Medication safety is an essential part of patient safety since adverse drug events are found 
to be the most common single type of adverse events (Council of Europe 2006a, Ruuhilehto 
et al. 2011). According to a recent literature review regarding patient safety incidents in 
primary care, incidents relating to diagnosis and prescribing were the most likely to result 
in severe harm (Panesar et al. 2015). Older people with multiple diseases and complex 
medications are most vulnerable to harm caused by medications (Linden-Lahti et al. 2009, 
Panesar et al. 2015, Eronen 2016). This chapter focuses on initiatives taken in Finland to 
manage risks in geriatric pharmacotherapy. 
5.1 Key initiatives to improve medication safety in geriatric 
pharmacotherapy in Finland  
Figure 11 illustrates major initiatives to promote rational pharmacotherapy of the aged in 
Finland since 2006, when the Ministry of Social Affairs and Health published an expert 
report of the status of geriatric pharmacotherapy in Finland (Kivelä 2006). 
A milestone in the efforts to improve medication safety of the aged was the Ministry of 
Social Affairs and Health’s report on the quality of geriatric care in Finland (Kivelä 2006, 
Figure 11). The report particularly highlighted deficiencies in appropriateness and safety of 
geriatric pharmacotherapy in outpatient and inpatient care. According to the report, more 
basic and continuing education programs in geriatric pharmacotherapy for physicians, 
nurses and practical nurses should be made available. A national interprofessional program 
to prevent harmful effects of pharmacotherapies in older adults should be started, and in that 
context good medical and non-medical treatments should be developed especially regarding 
sleep disorders, depression, pain and dementia, and to prevent injuries from falling. “Current 
care” recommendations should be improved by including specific recommendations 
regarding the care of elderly people. Semiannual collaborative medication reviews 
involving all health care providers participating in the pharmacotherapy of the older 
individuals were recommended. The report also highlighted that practical nurses should be 
able to monitor the positive and negative effects of the medicines and their appropriate 
administration. The role of pharmacies in medication counselling was emphasized. 
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MINISTRY OF SOCIAL AFFAIRS AND HEALTH 2006 
Expert Report on status of geriatric care in Finland (Kivelä 2006) 
 
 
BASED ON KIVELÄʼS (2006) REPORT 
MINISTRY OF SOCIAL AFFAIRS AND HEALTH ESTABLISHED A WORKING 
GROUP ON SAFE GERIATRIC PHARMACOTHERAPY FOR 2007–2009 
The Working Group coordinated the following projects:  
1. National guidelines for geriatric pharmacotherapy (Kivelä and Räihä 2007) 
2. Guidance letter to municipalities (Ministry of Social Affairs and Heath 2007) 
o Highlighted responsibilities of municipalities in assuring safe 
pharmacotherapy for the older residents in inpatient and outpatient care  
o Listed medications with highest risk requiring most urgent action  
o Emphasized interprofessional collaboration as a key in promoting safe 
pharmacotherapy of the aged  
o Recommended e.g., pharmacists involvement in conducting comprehensive 
medication reviews and providing automated dose dispensing services  
3. Development of a database on potentially inappropriate medications for the aged 
 
 
MINISTRY OF SOCIAL AFFAIRS AND HEALTH 2011 
Medicines Policy 2020: Major goal: pharmaceutical service is a part of the social 
welfare and healthcare service system 
 
 
BASED ON THE MEDICINES POLICY 2020 MINISTRY OF SOCIAL 
AFFAIRS AND HEALTH MANDATED THE FINNISH MEDICINES AGENCY 
TO START 2 MAJOR IMPLEMENTATION PROGRAMS IN 2012  
1. A program to promote interprofessional medication management of the aged 
2. Medicines Information Strategy to promote rational use of medicines through 
information and guidance  
 
 
ACT ON SUPPORTING THE FUNCTIONAL CAPACITY OF THE OLDER 
POPULATION AND ON SOCIAL AND HEALTH CARE SERVICES FOR 
OLDER PERSONS (2012, enacted in 2013) 
Sets several requirements for the municipalities concerning geriatric care 
 
 
GOVERNMENT PROGRAM 2015 
Aims to a massive social and health services reform in Finland 
Rational pharmacotherapy implementation program  
(Ministry of Social Affairs and Health 2015)  
Figure 11 Major policy initiatives to promote rational pharmacotherapy of the aged in Finland 
since 2006  
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Based on the above-mentioned report by Professor Kivelä the Ministry of Social Affairs 
and Health established a Working Group on Safe Geriatric Pharmacotherapy for the period 
of 2007–2009 (Figure 11). The working group coordinated the implementation of several 
of the actions recommended by the report (see more details in the next paragraphs). The 
most remarkable long-term effect of the report was establishment of the Act on Supporting 
the Functional Capacity and Social and Healthcare Services for the Aged which was 
launched in 2013 (Act 980/2012). The Act aims to ensure accessibility of social and 
healthcare services for the aged, and thus, supports their independent living. The Act sets 
several requirements for the municipalities i.e., special expertise must be available at least 
in the field of promotion of wellbeing and health, gerontological care and social work, 
geriatrics, pharmacotherapy, nutrition, interprofessional rehabilitation and oral health care. 
5.1.1 National guidelines on geriatric pharmacotherapy and a database of 
medication for the aged  
The first national guidelines in geriatric pharmacotherapy “Pharmacotherapy of the Aged – 
Iäkkäiden lääkehoito” was published in 2007 by the National Agency for Medicines and the 
Social Insurance Institution (Kivelä and Räihä 2007, Figure 11). The guidelines are based 
on national and international studies and critical reviews. General principles and special 
features of geriatric pharmacotherapy but also detailed guidance on pharmacotherapy for 
diseases and symptoms common in aged population are described in the booklet. It also 
provides examples of medication reviews.  
In 2008, the National Center for Pharmacotherapy Development (ROHTO) started the 
development of a database of medication for the aged (Lääke 75+) (Finnish Medicines 
Agency 2015a, Figure 11). The database encompasses information on potentially 
inappropriate and appropriate medications for the aged ≥75 years in order to support clinical 
decision-making for this special group of medicine users. Existing criteria measuring 
inappropriate prescribing and clinical consensus of expert opinions were used as a basis of 
the criteria (Ahonen 2011). The database is updated regularly by an expert group appointed 
by The Finnish Medicines Agency. The latest update was published at the end of 2015. 
Medicinal substances listed in the database are classified in four categories with color codes 
indicating how suitable each of the substances are for people aged ≥75 years. The categories 
are the following: A (green), suitable for the aged; B (grey), there is a little research 
evidence, practical experience or efficacy in persons over 75 years of age; C (yellow), 
suitable for the aged with certain precautions; and D (red), avoid using the substance for 
aged people. Each substance has a legend containing information on the effects, dosing and 
the most typical adverse reactions and interactions. 
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5.1.2 Medicines Policy 2020 and its implementation programs by Finnish 
Medicines Agency  
The Ministry of Social Affairs and Health established “The Medicines Policy 2020” 
document in 2011 (Ministry of Social Affairs and Health 2011a, Figure 11). The document 
was developed in collaboration with the key stakeholders of the pharmaceutical sector (more 
than 40 stakeholder organisations, such as authorities, universities, professional 
organisations, pharmaceutical companies and patients).  
According to the document, the main overall goal of pharmaceutical services by 2020 is 
to provide efficient, safe, rational and cost-effective pharmacotherapies to those who need 
them. The document emphasizes that pharmaceutical services are a part of the social welfare 
and health care service system and that client centeredness is a central goal in health care 
and pharmaceutical services. The document also highlighted the importance of patient 
empowerment and involvement in their own care. Interprofessional operational models and 
consultations in the implementation of the patient’s pharmacotherapy should be 
strengthened both in outpatient and inpatient care. Medication management in a 
collaborative process throughout healthcare was prioritized among the key strategic areas. 
The tasks of various health care professionals in collaborative medication review processes 
should be defined. The document also emphasized the importance of accessibility to reliable 
and evidence-based medicines information sources for both healthcare professionals and 
medicine users. 
Based on Medicines Policy 2020 Finnish Medicines Agency was mandated to start two 
major implementation programs in 2012 which focus on improving 1) interprofessional 
collaboration in medication management of the aged (Finnish Medicines Agency 2016, 
Figure 11) and 2) access and quality of medicines information to consumers and health care 
providers (Finnish Medicines Agency 2012, Figure 11).  
The development network for improving interprofessional collaboration in medication 
management of the aged comprises of several local development teams from various social 
and health care settings throughout the country with physicians, nurses, pharmacists and 
other health care professionals as team members (Finnish Medicines Agency 2016). The 
core is to learn from these teams on how to make teamwork and what are the facilitators and 
barriers for interprofessional teamwork (Kallio 2014, Finnish Medicines Agency 2016). The 
ultimate goal of the network is to establish national guidelines for interprofessional 
medication management of the aged.  The draft guideline was released for open hearing in 
the beginning of 2016 (Finnish Medicines Agency 2016). The draft guidelines emphasized 
development needs at structural, organizational and local network levels. It highlighted that 
current health care practices, including deficiencies in automated data transfer between, and 
even within, health care units, do not support patients’ seamless care that assures safe and 
rational pharmacotherapy.  
The main goal of the National Medicines Information Strategy, established in 2012, is 
to promote the rational use of medicines through information and guidance (Finnish 
Medicines Agency 2012, Hämeen-Anttila et al. 2012 and 2013). The key idea is to promote 
and coordinate the use of existing medicines information sources among the public and 
within social and health care services. The strategy also emphasizes taking into account 
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medicines information needs of special populations, the aged being mentioned among them. 
For them the strategy encourages to the development of new easy-to-read information 
sources. Challenges in the readability of package leaflets (e.g., small font size or too detailed 
text) was also noticed. The implementation of the medicines information strategy is also 
based on a network model. 
5.1.3 Government Program 2015 and an implementation program on rational 
pharmacotherapy by the Ministry of Social Affairs and Health  
Most recently, the importance of rational pharmacotherapy was acknowledged in the 
Finnish government program established in May 2015 (Government Program 2015). The 
government program aims to carry out a massive social and health services reform with the 
goal of improving implementation of comprehensive patient care, people’s functional 
capacity, and creating conditions for rational and cost-effective pharmacotherapy from the 
perspectives of the patient and society. The importance of clinical medication reviews 
among the aged is also mentioned (Ministry of Social Affairs and Health 2016b). The 
Ministry of Social Affairs and Health established the implementation program for rational 
pharmacotherapy in November 2015 (Ministry of Social Affairs and Health 2015). The 
implementation program will operate through a steering group and four working groups.  
The working groups will focus on 1) rational prescribing, dispensing and use of the 
medicines; 2) social and health care structures and data systems supporting rational 
pharmacotherapy, 3) evidence to guide the establishment of rational pharmacotherapy and 
4) drug innovations to support rational pharmacotherapy.  
5.2 Inventory of essential tools and services available in Finland 
for assuring safe pharmacotherapy of the aged 
In Finland, several tools exist to ensure medication safety in general, or specifically among 
the aged medicine users (Table 8). These tools have been developed for use by health care 
professionals or by the medicine users. Although only part of the tools are geriatric specific 
(G), they all can be utilized in order to improve medication safety of the aged. The tools 
range from product-specific medicine information databases to integrated systems assisting 
in clinical medication reviews (Table 8). The most extensive and widely used is the National 
Health Portal (Terveysportti) maintained by the Finnish Medical Society Duodecim 
(Finnish Medical Society Duodecim 2016a). Terveysportti is available for a charge 
throughout the health care, including community pharmacies. A comprehensive set of 
general current care guidelines exist in Finland, but special current care guidelines on 
geriatric pharmacotherapy are missing (Dimitrow et al. 2013). However, most of the general 
current care guidelines include a special section on geriatric patient care. Table 8 lists the 
tools available in Finland for improving medication safety according to the primary target 
users (health care professionals and medicine users). 
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5.3 Medication risk management initiatives in Finnish community 
pharmacies  
5.3.1 Pharmacy-led initiatives towards more clinically oriented services 
As an increasing proportion of aged people live in their own homes, the role of community 
pharmacies in promoting medication safety among the aged medicine users is growing. Finnish 
community pharmacies have actively taken action to promote the safe use of medicines (Tippa Project 
2014, Airaksinen et al. 2012, Leikola 2012). The first long-term coordinated effort was the TIPPA 
program (in English: Customized Information for the Benefit of the Patient from the Community 
Pharmacy) in 2000–2003, which aimed to improve patient safety by improving patient counselling 
(Tippa Project 2014, Puumalainen 2005, Kansanaho 2006). The program was coordinated by the 
authorities, universities, continuing education centers and professional organizations. Improved 
patient counselling led to increasing communication between pharmacists and patients (Kansanaho 
et al. 2005). This, in turn revealed several problems the people have with their medications and that 
could not be resolved by counselling, but required more comprehensive review of the medications. 
Thus, a follow-up program for TIPPA in 2004–2007 was implemented focusing on multidisciplinary 
collaboration and meeting the needs of medicine users (Tippa Project 2014). The key was to start 
accreditation training program for pharmacists to acquire clinical skills needed in comprehensive 
medication reviews (Tippa Project 2014, Peura et al. 2007, Leikola et al. 2009). This initiated a new 
chapter in the development of Finnish community pharmacy practice and extending services from 
dispensing to clinically-oriented collaborative services. 
5.3.2 Comprehensive medication review and other medication review/check services 
in community pharmacies promoting medication safety of the aged 
The Association of Finnish Pharmacies (AFP) has coordinated several pharmacy services related to 
medication risk management. In addition to the AFP, University Pharmacy also has developed its 
own modifications of the services. 
The CMR is the most important pharmacy service developed under the TIPPA follow-up program 
(Leikola 2012, Tippa Project 2014). CMR is a collaborative procedure for identifying, solving and 
preventing DRPs and is especially targeted to geriatric patients (Table 8, Leikola 2012, Leikola et al. 
2012). In CMR, an accredited pharmacist (1 ½ year curriculum (35 ECTS credits) encompassing 
distance and face-to-face learning) collaborates closely with health care professionals, especially with 
the patient’s physician. Patient’s clinical information (i.e., diagnoses, medications, laboratory results) 
is provided to the pharmacist by the physician. The pharmacist interviews the patient (and, if needed, 
the caregivers and/or nurses are involved) at the patient’s home using a structured scheme for patient 
interview and documentation. After a comprehensive review of the medications the pharmacist writes 
a report with findings and recommendations for the physician. To determine the actions, the report is 
discussed with the physician (possibly accompanied by the nurse) face-to-face. A follow-up interview 
with the patient is conducted after approximately 3 months. 
During the last years, CMR has stimulated discussion about geriatric pharmacotherapy risks and 
their management, and how pharmacists could take part in medication reviews (Ministry of Social 
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Affairs and Health 2011b, Ministry on Social Affairs and Health 2013). As CMR is a hard and time 
consuming process and realizing the fact that lighter, more easily out carried processes work in 
several medicine users, lighter versions have been modified (Ministry of Social Affairs and Health 
2011a, Table 8). Being the first really collaborative process in Finland, CMR has also met resistance 
in Finnish health care. However, according to a study conducted in 2013 as a national online survey, 
Finnish pharmacy owners are interested in developing medication review services, if the services 
would have national criteria and funding (Jokinen et al. 2014). The range of actual services available 
at the time of the study (year 2013; respondents: n=198) was the following: automated dose 
dispensing (ADD, discussed in next paragraph); 77%, medication review services; 23%, CMR; 21% 
(Jokinen et al. 2014). 
5.3.3 Automated dose dispensing services by community pharmacies  
Automated dose dispensing (ADD) is a collaborative service provided by community pharmacies in 
primary care. ADD means that patient’s regularly used medicines are machine packed into unit-dose 
bags for each time of administration (Sinnemäki et al. 2013 and 2014, Ministry of Social Affairs and 
Health 2016a). The pouches are delivered to the patient’s home, assisted living facilities or nursing 
homes. ADD service encompasses medication reconciliation followed with medication review 
conducted with interprofessional cooperation before the patient is entered into the service (Ministry 
of Social Affairs and Health 2016a). During the service, at least annual medication reviews are 
recommended. Although ADD services have been available for several years in Finland, ADD start-
up processes may still vary between different service providers (Sinnemäki et al. 2014). The new 
guidelines published by the Ministry of Social Affairs and Health (2016) aim to harmonize the 
practices. 
5.3.4 Tools to support medication safety in community pharmacies 
Finnish community pharmacies have excellent tools available for managing medication risks (see 
Table 8). Among the most important ones from the geriatric pharmacotherapy perspective is SALKO 
database, a medication review tool specifically designed to be used in community pharmacies 
(Leikola et al. 2013a and b). The SALKO database was developed by the Association of Finnish 
Pharmacies (AFP) to assist community pharmacists in evaluating medication-related risks among 
aged patients. SALKO is maintained by AFP and is updated regularly. The SALKO indicates 
sedative, anticholinergic and serotonergic properties of the medications, appropriateness for the 
elderly based on 4 different criteria (Laroche et al. 2007, Socialstyrelsen 2010, AGS 2012, Finnish 
Medicines Agency 2015a) and metabolization via 6 different Cytochrome P450 (CYP) enzymes.   
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5.4 Recent policy initiatives regarding community pharmacists’ 
involvement in managing safety risks in geriatric pharmacotherapy  
The role of community pharmacies in promoting safe pharmacotherapy has been discussed in two 
reports by The Ministry of Social Affairs and Health since 2011 (Ministry of Social Affairs and Health 
2011b, Ministry on Social Affairs and Health 2013). Regarding especially the aged medicine users 
with multiple medications, the first working group on the development of pharmacy services 
identified the following development needs: to further develop the automated dose dispensing 
procedure, to develop quality standards for medication reviews and to carry out a study to evaluate 
their cost-effectiveness (Ministry of Social Affairs and Health 2011b). 
In 2013 the Finnish Medicines Agency was again mandated by the Ministry of Social Affairs and 
Health to identify development needs regarding pharmaceutical services in both outpatient and 
inpatient care (Ministry on Social Affairs and Health 2013). The final report emphasizes that 
pharmacies and hospital pharmacies should have a greater responsibility in promoting rational 
pharmacotherapy. These reports provide a foundation for structuring pharmaceutical services as part 
of social and health care services, which are currently under reform (Government Program 2015).  
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6 An overwiew of Finnish studies on medicine use known to be 
potentially harmful for the aged  
6.1 Literature search 
A literature search of PubMed was performed using surnames of Finnish senior researchers known 
to be experts in geriatric care and geriatric pharmacotherapy. The search terms were: Ahonen J, Bell 
JS, Enlund H, Finne-Soveri H, Hartikainen S, Hosia-Randell H, Huupponen R, Isoaho R, Jyrkkä J, 
Kivelä SL, Leikola S, Linjakumpu T, Nurminen J, Pitkälä K, Puustinen J, Strandberg T, Sulkava R, 
Taipale H, Tilvis R, Räihä I, Salonoja M. English language peer reviewed articles published between 
1.1.2000–31.12.2015 describing studies conducted in Finland among people ≥65 years were searched 
with no limitation on the type of study. This overview has no aim to address the results of the studies 
but it focuses on what different aspects has been studied on medicine use that can be potentially 
harmful for the aged.  
6.2 Results 
Altogether 75 research articles were found. Majority (87%; n=65/75) of the articles focused on 
describing trends in medication use among the aged, polypharmacy and potentially inappropriate 
prescribing and medicine use (Figure 12). Minority (13%; n=10/75) described interventions aiming 
to reduce potentially inappropriate prescribing or medicine use and/or influence of these 
interventions. The distribution of these articles over time is presented in Figure 12. 
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Figure 12 Distribution over time of the research articles describing A) polypharmacy, B) potentially 
inappropriate prescribing and medicine use C) interventions aiming to reduce potentially 
inappropriate prescribing and medicine use in Finland since 2000 (number of articles 
according to the publication year)  
6.2.1 Articles describing medicine use known to be potentially harmful for the aged  
6.2.1.1 Trends in medication use of the aged regarding polypharmacy  
Altogether five (7%) studies described polypharmacy (Linjakumpu et al. 2002, Jyrkkä et al. 2006, 
Jyrkkä et al. 2009a and b, Jyrkkä et al. 2011, Table 9). Most of these articles were prevalence studies 
(prevalence, changes in prevalence over time) and were conducted in outpatient care in local 
communities.  
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6.2.1.2 Potentially inappropriate prescribing and medicine use  
A majority (81%, n=60) of the articles described potentially inappropriate prescribing and medicine 
use (Table 12). Of them, 40 (66.6%) were conducted in outpatient care (Table 10). Registers, patient 
interviews and patient interview and medical records/charts were most often used as a source of data. 
These studies most often reported prevalence of the use of potentially harmful medicines, changes in 
the use of these medicines, factors associated with the use and/or the association between the use of 
those medicines with predominantly determined ADEs (e.g., falls, fractures, cognitive decline, 
delirium, orthostatic hypotension, poor muscle strength or balance) or other outcomes (e.g., 
hospitalization, health service utilization, mortality, morbidity, psychological well-being). Table 10 
shows the settings and study populations of the studies describing inappropriate prescribing and 
medicine use in the aged.  
Table 10.  Settings and study populations of the studies describing inappropriate prescribing and 
medicine use in the aged (n=60)  
Setting % (n) 
Outpatient care 66.6 (40) 
Long-term care 21.6 (13) 
Outpatient care and long-term care 5 (3) 
Hospital setting 1.7 (1) 
Long-term care and hospital setting 1.7 (1) 
Acute ward 1.7 (1) 
During admission 1.7 (1) 
The size of the study population % (n) 
1–100 0 (0) 
101–200 5 (3) 
201–500 15 (9) 
501–1000 30 (18) 
1001–10 000 35 (21) 
10 001–100 000 13 (8) 
>100 000 2 (1) 
 
Of the 60 articles, six (10 %) described studies using existing criteria as measures of 
appropriateness, such as Beers criteria or categorization of the Finnish Medicines Agency for 
potentially inappropriate medicine use among the aged (Pitkälä et al. 2002, Fialova et al. 2005, Raivio 
et al. 2006, Hosia-Randell et al. 2008, Leikola et al. 2011, Bell et al. 2013, Tables 11 and 12). Of 
these studies, only one study covered the entire Finnish non-institutionalized population aged ≥65 
years (n= 841 509) (Leikola et al. 2011). Single medicines, medicine groups or medicine 
combinations known to be harmful for the aged were studied in 90% (54/60) of the articles (Tables 
11 and 12). Of these, Central Nervous System (CNS) medications was the most studied therapeutic 
group (81%, n=44), antipsychotics, anticholinergics and sedatives being the most studied subgroups.  
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Table 11. Measures of potentially inappropriate prescribing and medicine use used in the studies (n=60) 
Measure  n 
Existing criteria, total 6 
Beers 1997 criteria (Beers 1997) 
Beers 2003 criteria (Fick et al. 2003) 
Beers 2003 criteria (Fick et al. 2003) + SFINX-interactions 
Database of medication for the elderly (Finnish Medicines Agency 2011) 
Beers 1997 (Beers 1997), 2003 (Fick et al. 2003) and McLeod criteria (McLeod et al. 
1997) 
2 
1 
1 
1 
1 
Medicines, medicine groups and combinations of medicines, total 54 
Central Nervous System (CNS) medicines (total) 44 
CNS-medicines (the entire group) 
Psychotrophics 
Psychotrophics and analgesics 
Psychotrophics and sedatives 
Psychotriphics, analgesics and opioids 
 
Antipsychotics 
 
DAPs 
DAPs and sedatives 
DAPs, sedatives and antipsyhotics 
DAPs and ChELs 
 
Sedatives 
 
Antidepressants 
 
Antiepilectics 
1 
9 
1 
1 
1 
 
8 
 
6 
3 
1 
1 
 
10 
 
1 
 
1 
Other medicines and medicine groups, total 9 
Analgesics 
Opioids 
SSRIs, NSAIDs/Aspirin and gastroprotective medicines 
Laxatives (regularly) 
PPIs 
All used medicines 
Prescription medicines 
3 
1 
1 
1 
1 
1 
1 
Interactions, total 1 
Drugs interacting with warfarin 1 
ChEL=Cholinesterase Inhibitor, DAP=Drug with anticholinergic properties, SFINX= Swedish, Finnish, Interaction 
X-referencing database, SSRI=Selective Serotonin Reuptake Inhibitor, NSAID=Nonsteroidal Anti-Inflammatory 
Drug, PPI=Proton Pump Inhibitor 
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92 
6.2.2 Articles describing interventions aimed to reduce potentially inappropriate 
prescribing and medicine use 
Ten (13%) of the 75 articles described attempts to reduce DRPs among the aged (Pitkälä et al. 2001, 
Lampela et al. 2010 and 2013, Rikala et al. 2011, Leikola et al. 2012, Lähteenmäki et al. 2013, 
Nurminen et al. 2014, Puustinen et al. 2014, Pitkälä et al. 2014, Juola et al. 2015, Table 13) most of 
which were randomized controlled trials (RCTs) (Pitkälä et al. 2001, Lampela et al. 2010 and 2013, 
Rikala et al. 2011, Lähteenmäki et al. 2013, Nurminen et al. 2014, Pitkälä et al. 2014, Puustinen et al. 
2014, Juola et al. 2015, Table 13). Eight (80%) of the studies were conducted in outpatient care 
(Pitkälä et al. 2001, Lampela et al. 2010 and 2013, Rikala et al. 2011, Leikola et al. 2012, Lähteenmäki 
et al. 2013, Nurminen et al. 2014, Puustinen et al. 2014) and two (20%) in long-term care facilities 
(Pitkälä et al. 2014, Juola et al. 2015). The size of the study population varied from 89 to 700. The 
studied interventions were: short term tight control conditions of day hospital care (Pitkälä et al. 
2001), pharmacist-led CMR (Leikola et al. 2012), medication review as a part of Comprehensive 
Geriatric Assessment (Lampela et al. 2010 and 2013, Rikala et al. 2010), psychosocial support 
provided by a physician for sedative withdrawal (Lähteenmäki et al. 2013, Nurminen et al. 2014, 
Puustinen et al. 2014) and training the nursing staff on harmful medicine use (Pitkälä et al. 2014, 
Juola et al. 2015). 
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7 Aims of the study  
This PhD study is a part of a larger research programme carried out in the Universities of Helsinki 
and Turku aiming to search solutions to improve medication safety of the aged. This study consists 
of 4 substudies (I–IV) which describe development and validation of a Drug-related Problem Risk 
Assessment Tool (DRP-RAT) for use by practical nurses (PNs) taking care of home-dwelling clients 
≥65 years, aiming to involve PNs more systematically in medication risk management of their clients.  
 
The aims of the substudies (I–IV) were: 
 
1) To systematically review the literature on existing criteria that measure inappropriate 
prescribing in individuals aged 65 years and older (I) 
2) To develop and content validate a Drug-related Problem Risk Assessment Tool (DRP-RAT) 
for use by practical nurses (PNs) taking care of home-dwelling clients aged ≥65 years (II) 
3) To evaluate the feasibility of the DRP-RAT among practical nurses in home care (III) 
4) To assess the reliability of the medication risk assessments conducted by PNs by using DRP-
RAT and to identify clinically most significant DRPs needing action (IV) 
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8 Materials and methods 
The development of the final DRP-RAT consisted of two major phases. First, the development of the 
draft DRP-RAT (Phase I). Second, validation of the DRP-RAT (Phase II). The validation of the tool 
included three steps: 1) content validation 2) assessing the feasibility of the content validated tool 
among PNs and, 3) testing the validity of the tool in clinical practice (Figure 13, Table 14). This study 
applied both quantitative and qualitative methods (Table 14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 Outline of the study  
 
Development of the draft DRP-RAT 
1. Two systematic literature reviews 
(Study I, Dimitrow et al. unpublished) 
2. Expertise of the Research Group 
3. Consultation of a geriatrician not involved in the 
Research Group 
 
Content validation of the draft DRP-RAT 
(Study II) 
Content validity of the draft tool was determined 
by a three-round Delphi survey with a panel of 18 
experts in geriatric care and pharmacotherapy 
Feasibility of the final DRP-RAT  
(Study III) 
Feasibility evaluation of the final tool among 
practical nurses in home care of two towns in 
southern Finland 
Testing the validity of the final DRP-RAT in 
clinical practice 
(Study IV) 
Experienced geriatricianʼs reliability evaluation 
of practical nursesʼ risk-assessments by using  
DRP-RAT 
The geriatrician identified the clinically most 
significant DRPs needing action 
Phase II 
 V
alidation process 
Phase I 
D
evelopm
ent 
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Table 14. Materials and Methods used in substudies (I—IV) 
STUDY 
(year) 
OBJECTIVES METHODS  MATERIALS ANALYSIS 
I  
(2010) 
 
To systematically 
review the literature 
on existing criteria 
that measure 
inappropriate 
prescribing in 
individuals aged 65 
years and older. 
The review focused 
on the methods 
employed to 
develop the criteria 
and the contents of 
the criteria with 
time restriction 
1.1.1990–17.6.2010 
Systematic 
literature 
review   
 
Original English language studies 
(n=14) describing criteria for 
measuring inappropriate prescribing in 
individuals aged 65 and older  
Qualitative analysis  
II 
(2010) 
 
To develop and 
content validate a 
Drug-related 
Problem Risk 
Assessment Tool 
(DRP-RAT) for use 
by practical nurses 
(PNs) taking care of 
home-dwelling 
clients ≥65 years 
Three-round 
Delphi survey  
Contents of the draft DRP-RAT based 
on two systematic literature reviews 
and the expertise of the research group 
Quantitative and 
qualitative analysis 
 
III 
(2011) 
To evaluate the 
feasibility of the 
DRP-RAT among 
PNs in home care 
Cross-
sectional 
feasibility 
study using 
triangulation  
Qualitative and quantitative data 
collected during training the PNs 
(n=36) about purpose and use of the 
DRP-RAT in home care of two towns. 
Qualitative data: face-to-face 
discussions i.e., open and structured 
group discussions and PNsʼ open 
comments in the feedback forms 
Quantitative data: PNsʼ responses in 
the DRP-RATs concerning risk 
medicines listed in the tool, medication 
lists copied by the PNs 
Qualitative content 
analysis of face-to-
face discussions and 
feedback forms 
Quantitative analysis 
of completed DRP-
RATs; descriptive 
statistics 
(frequencies, 
percentages, means, 
standard deviations) 
IV 
(2013) 
To assess reliability 
of medication risk 
assessments 
conducted by PNs 
by using DRP-RAT 
and to identify 
clinically most 
significant DRPs 
needing action (i.e., 
validity of the 
DRP-RAT in 
clinical practice) 
Cross-
sectional 
retrospective 
study using 
triangulation 
Geriatrician’s appraisal of the 
reliability of medication risk 
assessments conducted by PNs by 
using the DRP-RAT.  
Qualitative and quantitative data 
collected from study forms including 1) 
DRP-RAT to be completed by PNs 
(Phase I of the study), 2) a section to be 
completed by a geriatrician to assess 
the reliability of PNsʼ responses in the 
DRP-RAT (Phase II of the study) 
Geriatricians case reports of each 
patient 
Qualitative content 
analysis of the 
geriatrician’s open 
comments 
Quantitative analysis: 
descriptive statistics 
(frequencies, 
percentages, 
confidence interval 
for percentages, 
means, ranges) 
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8.1 Systematic review of prescribing criteria to evaluate the 
appropriateness of drug treatment in individuals aged 65 and older (I) 
8.1.1 Search strategy 
 
The MEDLINE (Ovid) and PubMed databases were searched from January 1, 1990 to July 17, 2010. 
The following search terms were used: inappropriate prescribing, suboptimal prescribing, 
inappropriate medication, inappropriate practices (Drug Prescriptions), measure, screening tool, 
criteria, elderly, Beers criteria, and Medication Appropriateness Index (MAI). In addition to original 
research studies, the search covered reviews, systematic reviews, and meta-analyses. The search from 
these databases was supplemented with a manual search from the reference lists of accepted articles 
and articles found in authors’ files. 
8.1.2 Inclusion criteria  
Original studies describing criteria for measuring inappropriate prescribing were included in this 
study if they involved individuals aged 65 and older, were written in English, and described the 
development methods for the criteria.  
8.1.3 Literature search  
The search produced 531 potentially relevant publications (I: Figure 1). The titles of these articles 
were read, and 361 were excluded because the titles showed that the articles were not relevant 
according to the inclusion criteria. Next, the abstracts of the publications potentially relevant 
according to their titles were reviewed. In this phase, 138 publications were excluded because the 
abstracts showed that the articles did not describe the development of the criteria. Twelve publications 
were excluded because they were duplications. Two researchers read the whole texts of the remaining 
20 publications. Both independently excluded the articles not meeting the inclusion criteria. 
Disagreements were resolved by discussion. In this phase, 12 articles met the inclusion criteria. The 
manual search from the reference lists of the included 12 articles produced three relevant publications 
not found in the previous systematic database search, and one additional relevant article was identified 
in the manual search of the researcher’s own bibliographic database. Thus, 16 original studies met 
the inclusion criteria and described 14 criteria altogether. Two researchers independently classified 
the nature of the criteria employed (explicit vs implicit). 
8.1.4 Outcome measures and data analysis  
The original articles were read, and criteria to assess inappropriate prescribing in individuals aged 65 
and older and the nature of the criteria (explicit vs implicit), information about the country where the 
criteria were developed, evidence used to determine the criteria, validation methods, target groups to 
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which the criteria applied, and the contents of the criteria (which different elements of inappropriate 
prescribing they measure) were analysed as primary outcomes. The amount of clinical information 
included in the criteria was analysed as secondary outcomes. The literature review was updated in 
2012 covering articles until June 2012 (Dimitrow et al. 2013). 
8.2 Delphi survey to validate the content of a tool for assessing risks for 
drug-related problems in the aged ≥ 65 years (II) 
8.2.1 Development process  
The DRP-RAT was developed in two major phases (II: Figure 1), namely by 1) developing a draft 
Tool on the basis of two systematic literature reviews and the clinical expertise of the Research Group, 
and 2) determining the content validity of the Tool by a three-round Delphi survey.  
8.2.1.1 Literature reviews 
The literature on existing criteria for assessing inappropriate prescribing in patients aged ≥65 years 
was systematically reviewed (I). In addition to the above mentioned systematic literature review on 
potentially inappropriate medications for the aged, another systematic search was conducted 
searching existing tools designed to screen aged patients at risk for DRPs (Chapter 4.2.3, Dimitrow 
et al. unpublished). The following search terms were used: (elderly or aged or ageing) and 
(medication-related problem or drug-related problem or drug-therapy problem) and (risk) and 
(screening tool or tool or form). English language articles published during 1985–2010 were searched 
in the following databases: Evidence Based Medicine Database, Web of Knowledge, Scopus and 
Cinahl.  
8.2.1.2 Development of the draft DRP-RAT  
According to the findings of the first systematic review (I), 1) medicines and medicine classes 
recognized to pose higher risks for the aged, and 2) potential geriatric-specific ADRs caused by these 
medicines were identified. Second, according to the findings of the unpublished systematic review 
that focused on existing age-specific (≥65 years) screening tools (n=6) (Chapter 4.2.3), the most 
commonly mentioned prognostic indicators for DRPs were listed. The review also revealed some 
other factors to be considered, particularly the structure of the tool and focusing the screening on 
potentially harmful ADRs instead of producing a long list of problematic medicines (Pit et al. 2008). 
Both of these systematic literature reviews’ findings were integrated into the draft Tool. Our Research 
Group’s clinical experience was used in this phase, as well as that of an experienced geriatrician who 
was not a member of the Research Group. 
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8.2.2 Content validation of the DRP-RAT 
8.2.2.1 Delphi method 
The Delphi method is a systematic technique for formulating a group judgment concerning subject 
matter for which the information is incomplete or lacking entirely (Dalkey and Helmer 1962, 
Campbell and Cantrill 2001). Its validity relies on a panel of experts having been carefully selected, 
that their individual judgements be provided independently and anonymously via questionnaires in 
two or more rounds, and that there be aggregated feedback between rounds. 
Face validity of the presented DRP risk assessment items of the draft DRP-RAT were assessed 
using 1-round pilot Delphi survey with a panel of 6 pharmacists accredited for CMR (Leikola et al. 
2009, Leikola 2012). Contents of the draft DRP-RAT was validated using a three-round Delphi 
survey with a panel of 18 experts in geriatric care and pharmacotherapy (11 physicians, 4 nurses and 
3 pharmacists) via software called eDelfoi (Metodix 2010). 
During the first and the second Delphi rounds, the panelists rated the suitability of the presented 
items in assessing risks for DRPs in the aged ≥65 years. An agreement by ≥80% of the panel on an 
item was determined. Round one also included a final open-ended question: If you think that the draft 
risk assessment tool ignores some essential aspects of medication risks in routine community clinical 
practice, please identify each of them. During the third Delphi round, the panelists rated the 
importance of the items in final DRP-RAT using rating scale 5 (important) – 1 (unimportant).  
Before each Delphi round (pilot and actual rounds), it was stressed to the panelists that the final 
Tool was meant to be administered by PNs and that the panelists should consider a typical PN’s ability 
to assess the items in clinical practice. The panelists’ guidance also emphasized the goal of developing 
a tool which 1) focuses on the most important predictors for DRPs in the aged, 2) is easy to use in the 
time-constraints of routine practice, and 3) requires only modest training for PNs.  
8.3 Feasibility of the DRP-RAT among practical nurses (III) 
Feasibility of the final DRP-RAT among PNs (i.e., PNsʼ ability to reliably review their clients’ 
medications by using the Tool) was assessed in two HC teams from two towns (A and B) in southern 
Finland (town A approx. 320 HC clients and 60 HC workers; town B approx. 2000 HC clients and 
300 HC workers in total). A group of 11 PNs in town A and 25 PNs in town B participated in the 
study. In both towns, the PNs were trained on the purpose and use of the DRP-RAT and each HC 
unit’s principles in medication management. The training was based pedagogically on constructive 
learning, applying experiential learning methods and depended on participants’ active involvement. 
The training consisted of a day-long interactive workshop and involved reviewing four self-selected 
clients’ medications by using the Tool (one as a pre-assignment before the workshop day to become 
familiar with the Tool, and three as post-assignments after the day). Educational content of the 
training was based on the DRP-RAT. After the training four members of the research group met with 
health service managers of both towns’ HC services to inform them about what was learned about 
PNsʼ educational needs and needs to improve medication management processes.  
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Triangulation, i.e., combination of different methods and data was used to evaluate the feasibility 
of the Tool (Table 15) (Smith 2002). Quantitative data were gathered from completed post-
assignments in town B (collecting the study materials was pilot-tested in town A) and qualitative data 
were gathered both in towns A and B from 1) face-to-face discussions, i.e., open and structured group 
discussions during the workshop day and 2) open questions in the feedback forms. Data obtained 
from open and group discussions and the feedback forms were combined prior to analysis. Statistical 
analyses were performed using SPSS Statistical Software 21.0.  
8.3.1 Study permission and ethics committee opinion  
This was a health service research aiming to assess PNsʼ ability to reliably review their clients’ 
medications by using the Tool. The HC clients were not provided any care and thus, all patient data 
were collected and analysed anonymously. Thus, no ethical approval was needed. The study 
permission was allowed by the health service managers of both towns’ HC units.  
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8.4 Validity of the DRP-RAT in clinical practice (IV) 
The study was conducted in the four months from September to December 2013 in the HC of Härkätie 
Health Centre in Lieto (HC clients, n=170; entire HC staff, including nurses and PNs, n=31). Lieto is 
a municipality with approximately 17 000 inhabitants located in southwestern Finland. Härkätie 
Health Centre is a primary care unit and part of the public health care system in Finland, which is the 
dominating health care system covering the entire population through public social insurance (Teperi 
et al. 2009). 
8.4.1 Study design  
PNs (n=26) working in HC of the Härkätie Health Centre in Lieto and a clinically experienced 
physician qualified in geriatrics were recruited for the study. PNs were trained to use the DRP-RAT 
(III). A data collection form was developed to facilitate the reliability comparisons of PN-conducted 
medication risk assessments (IV: Table 1). The form included 1) a section to be completed by a PN 
(the first phase of the study) and 2) a section to be completed by the geriatrician (the second phase of 
the study). Both the participating PNs and the geriatrician were given oral and written instructions 
for completing their sections of the form. 
8.4.1.1 First phase of the study: DRP Risk Assessments by PNs  
The PNʼs section in the data collection form included 1) DRP-RAT, 2) a short test assessing the 
client’s alcohol use (3 alcohol consumption questions from The Alcohol Use Disorders Identification 
Test, i.e., AUDIT C) (Bush et al. 1998, Babor et al. 2001), and 3) space for PN’s open comments (IV: 
Table 1). PNs were trained on the purpose and use of the DRP-RAT and on the HC unit’s principles 
in safe medication management (III, Ministry of Social Affairs and Health 2005). 
After a 1-day interactive training the PNs reviewed the medications of 1–3 self-selected clients 
using the DRP-RAT (III). They were instructed to select for review such clients who were supposed 
to be at risk of DRPs. They also were asked to print the same client’s medication list from the health 
centre’s medical record and to complete an AUDIT C test for alcohol consumption (Bush et al. 1998, 
Babor et al. 2001). They returned the completed documents to the HC office. Before forwarding the 
documents to the geriatrician, two researchers checked them to ensure they were fully and 
appropriately completed.  
8.4.1.2 Second phase of the study: DRP risk assessment and medication review by the 
geriatrician  
The geriatrician was asked to review each client’s medications using three different methods which 
differed in the amount of clinical patient information available (IV: Table 1, see also Table 16). When 
conducting each review the geriatrician was asked to be “blind” to the results of the other reviews for 
the same client. Based on each of the three reviews and her clinical geriatric expertise, the geriatrician 
was asked to classify whether the client was “an at-risk patient” (i.e., being at risk for clinically 
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significant DRPs needing more comprehensive medication review) or “not an at-risk patient”. If the 
geriatrician classified the client as “an at-risk patient” based on Medication Review by Method 1 
(DRP-RAT information and medication list) she was asked to tick those PN-identified risk predicting 
notes in the Tool that she regarded as clinically significant risk factors. 
The Medication Review Method 2 was regarded as “gold standard” in this study (Table 16). If the 
patient was classified as “an at-risk patient” using Method 2, the geriatrician was asked to write an 
open case report about the identified DRPs and to document the DRPs and their causes according to 
the Pharmaceutical Care Network Europe (PCNE) classification V6.2 (PCNE 2010, described more 
detailed in Chapter 2.1.2) on a structured data collection form (the geriatrician had received a short 
training to use the PCNE classification). Other aspects studied are presented in Table 16. 
8.4.1.3 Study permission and ethics committee opinion  
Ethical approval for the study was received from the Ethical Board of Southwest Finland. The HC 
clients gave a written informed consent to participate in the study. The study permission was received 
from the health service manager of Härkätie HC unit. 
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Table 16. Aspects studied and methods used for data analysis in determining the DRP Risk Assessment 
Toolʼs ability to provide reliable clinical patient information to assist the physician in 
clinical decision making 
Aspects Studied  Data analysis 
The DRP-RATʼs ability to assist in identifying older HC clients at risk 
of clinically significant DRPs 
Medication reviews conducted by the geriatrician (were performed 
without direct patient contact): 
Method 1: Medication Review based on the DRP-RAT with Audit 
C completed by the PNs and the medication lists printed from the 
health centreʼs medical records  
Method 2 (usual care in health centre in cases the physician does not 
meet the patient): Review based on the health centre’s medical 
records (“gold standard”1) of this study) 
Medical records encompass the following patient data a) 
visits in health centre, b) clinical examinations (health status, 
anamnesis, conclusions), c) medication lists, d) laboratory 
test results, e) hospitalizations, f) HC workersʼ open 
comments about their home visits  
Method 3: Review based on Methods 1 and 2 together = all client 
information available 
Frequencies and percentages (95% CI) of the 
identified “at-risk patients” resulting from 
each Medication Review Method were 
reported 
 
 
 
 
Geriatrician’s evaluation about the validity of the PNs’ 
recommendations for action to resolve potential DRPs listed in the 
DRP-RAT  
Frequencies and percentages of “valid” and 
“invalid” recommendations were reported. 
Results of qualitative analysis of the 
geriatrician’s justifications were reported 
Geriatrician’s assessment of the DRP-RATʼs ability to provide 
clinically important and timely patient information for clinical decision 
making 
Frequencies and percentages of “yes”, “no” 
and “some additional information” were 
reported. Results of qualitative analysis of 
the geriatrician’s justifications were reported 
Relevance of the questions in the DRP-RAT i.e., prevalence of the 
DRP risk predicting notes reported by the PNs in the completed DRP-
RATs in the study sample  
Frequencies and percentages of the risk 
predicting notes on each question of the 
Tool were reported 
Clinical significance of potential DRPs reported by PNs confirmed by 
an experienced geriatrician. Significance was determined as follows; 
the more often the geriatrician evaluated the PNsʼ DRP risk predicting 
note in the Tool as a risk factor (i.e., those PNsʼ risk predicting notes 
in the Tool that the geriatrician had ticked in order to be risk factors 
during Medication Review Method 1) the more important the question is  
Frequencies of the PNʼs positive risk 
predicting notes that the geriatrician 
evaluated as clinically significant risk 
factors needing action 
DRPs and their potential causes in the study sample documented by 
the geriatrician and the associated drugs or drug groups using 
Medication Review Method 2. 
Geriatrician’s case reports of each patient and the PCNE -classification 
V6.2 done by the geriatrician were analysed.  
(Two researchers independently double-checked the geriatricianʼs 
PCNE-classifications by comparing the case reports and the PCNE-
classifications. Obscurities were resolved by discussion) 
The documented DRPs, causes of DRPs and 
the associated drugs or drug groups are 
reported 
Time the geriatrician spent reviewing one client’s medication using the 
DRP-RAT 
Time scale, the mean time the geriatrician 
spent reviewing one client’s medication with 
the Tool are reported 
1) In normal practice, physicians working in health centre are often forced to make decisions concerning their HC patient’s 
medication without personal patient contact but relying only on a health centre’s medical records   
AUDIT-C=3 alcohol consumption questions from The Alcohol Use Disorders Identification Test (Bush et al. 1998, Babor et al. 2007) 
DRP-RAT=Drug-related Problem Risk Assessment Tool (II), PCNE=Pharmaceutical Care Network Europe (PCNE 2010) 
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9 Results 
9.1 Systematic review of prescribing criteria to evaluate the 
appropriateness of drug treatment in individuals aged 65 and older (I) 
9.1.1 Retrieved criteria  
Researchers in the United States were early developers of the criteria; the first criteria being 
developed in the early 1990s (Beers et al. 1991, Hanlon et al. 1992, Lipton et al. 1993, I: Table 1, 
Table 17). In Europe, the first consensus-validated criteria were developed in France more than a 
decade later (Laroche et al. 2007). Ten (71%) of the 14 criteria found in the literature search were 
explicit (Beers et al. 1991, Beers 1997, McLeod et al. 1997, Naugler et al. 2000, Zahn et al. 2001, 
Fick et al. 2003, Laroche et al. 2007, Gallagher et al. 2008, Rognstad et al. 2009, Maio et al. 2010), 
three (21%) were implicit (Hanlon et al. 1992, Lipton et al. 1993, Jeffery et al. 1999), and one 
contained explicit and implicit criteria (Basger et al. 2008). Most explicit criteria have been validated 
using consensus methods (Beers et al. 1991, Beers 1997, McLeod et al. 1997, Zahn et al. 2001, Fick 
et al. 2003, Laroche et al. 2007, Gallagher et al. 2008, Rognstad et al. 2009, Maio et al. 2010). All 
implicit criteria were validated using patient medical records (Hanlon et al. 1992, Lipton et al. 1993, 
Jeffery et al. 1999). Target groups, basis of the criteria, development methods and description of the 
contents of the criteria are presented in Table 17.  
Beers criteria and its updates are the most well-known and widely used criteria (Beers et al. 1991, 
Beers 1997, Fick et al. 2003, AGS 2012, AGS 2015). The most recent update of the Beers criteria 
was published in 2015 by the American Geriatrics Society (AGS 2015). Most explicit criteria, even 
the newest ones, have utilized Beers criteria and/or its updates as a basis of the criteria (Figure 14). 
Also exceptions exist: the Irish STOPP and START criteria was based on evidence-based literature 
and experience of the investigators (Gallagher et al. 2008). This two-part tool takes into account both 
inappropriate prescribing and underprescribing among the aged 65 years and older. Due to expanding 
therapeutic evidence an update of the criteria was published in 2015 (OʼMahony et al. 2015). In 
Australia, Basger and colleagues (2008) developed their criteria based on the most frequent 
medications prescribed to Australians and the most frequent medical conditions for which older 
Australians consult medical practitioners. Australian indicators were updated and validated in 2012 
(Basger et al. 2012).  
9.1.2 Contents of the criteria  
Most criteria measure pharmacological appropriateness of prescribed medicines (Dimitrow et al. 
2013). The Australian Tool (Basger et al. 2008 and 2012) and MAI (Hanlon et al. 1992) goes 
somewhat beyond pharmacological aspects assessing also risks related to the medication use process: 
(i.e.,  MAI advices to takes into account practical directions (Hanlon et al. 1992), while the Australian 
Tool recommends monitoring the effects of medication and laboratory values (e.g., blood pressure, 
pain, itch or discomfort that interferes with daily activities, international normalized ratio (INR), 
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creatinine clearance) and, to offer smoking cessation options with certain diseases (Basger et al. 2008 
and 2012).  
The majority of the instruments represent a quantification of misprescribing (Dimitrow et al. 
2013). They list potentially inappropriate medications (e.g., anticholinergics, sedatives, neuroleptics, 
nonsteroidal anti-inflammatory drugs, long-acting sulfonylureas), most common harmful drug-drug 
and drug-disease interactions and potential geriatric-specific adverse effects related to them. They 
also describe doses and durations of medications that should not be exceeded. Six criteria concern 
overprescribing (Hanlon et al. 1992, Lipton et al. 1993, Basger et al. 2008, and 2012, Laroche et al. 
2007, Gallagher et al. 2008, Rognstad et al 2009). Three of the 14 criteria concern underprescribing 
(Jeffery et al. 1999, Gallagher et al. 2008, Basger et al. 2008), two of them being particularly 
developed for detecting underprescribing (Jeffery et al. 1999, Gallagher et al. 2008). Through time, 
explicit criteria have evolved more comprehensive and thus, their use requires more clinical patient 
data. For example, Beers 1991 (Beers et al. 1991) criteria list only PIMs, while the recent update 
(AGS 2015) includes PIMs, drug-disease and drug-syndrome PIMs, drugs to be used with caution, 
drug-drug interactions and PIMs based on kidney function. 
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9.2 Delphi survey to validate the content of a tool for assessing risks for 
drug-related problems in the aged ≥65 years (II)  
9.2.1 Results of the Delphi rounds  
Expert panelists achieved consensus on 48 of 102 (47%) items (Figure 15, II: Figure 1). In addition 
to these 48 consensus items, 11 items were retained according to the research group’s judgement, 
resulting in the 59-item final DRP-RAT (each individual item of the final tool’s multicomponent 
items are discussed here as items (II: Table 1). Outline of the development and validation process of 
the DRP-RAT and results of the Delphi rounds are illustrated in Figure 15 (II: Figure 1).   
9.2.1.1 Contents of the final DRP-RAT  
The final version of the tool consists of four main sections: 1) Basic Client Data 2) Potential Risks 
for DRPs in Medication Use, 3) Characteristics of the Client’s Care and Adherence, and 4) 
Recommendations for Actions to Resolve DRPs (Appendix, II: Table 1).  
Section 1 (Basic Client Data) focuses on basic client demographic data (age, gender, living alone). 
It also includes an indicator of whether the client has an up-to-date medication card/list and who 
administers the client’s medications.  
Section 2 (Potential Risks for DRPs in Medication Use, 10 main items) focuses on symptoms 
potentially suggestive of ADRs, use of high-risk medicines and risks posed by polypharmacy. It also 
includes items of initiation of a new medication, and concomitant use of nonprescription medicines 
or vitamins with prescription medicines.  
Section 3 (Characteristics of the Client’s Care and Adherence, 8 main items) includes information 
about the client’s health, adherence to their therapeutic regimen and involvement in one’s care, the 
health care setting, health care units recently visited by the client, and the number of care-taking 
physicians. 
Section 4 (Recommendations for Actions to Resolve DRPs) encompasses seven interventions that 
PNs can recommend for resolving potential DRPs for those at risk. The PNsʼ recommendations need 
to be based on a risk assessment resulting from the information gathered by using the DRP-RAT. 
9.2.1.2 Importance of the items in the final DRP-RAT for predicting DRP risks 
The panelists of the third Delphi round (n=16) ranked two items as the most important for predicting 
DRP risks in the aged: 1) the item indicating whether the client has an up-to-date medication list, and 
2) the item assessing the client’s adherence to his/her medication. All of the items in the final tool 
were rated either as important or moderately important in predicting DRP risks for those ≥65 years 
(Figure 15, II: Table 2). 
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Figure 15 Outline of the development of the DRP-RAT and validation of its content by Delphi method 
The draft DRP-RAT  
Two systematic reviews (I, Dimitrow et al. unpublished) 
Expertise of the Research Group 
Consultation of a geriatrician not involved in the Research Group 
Expert Panel Selection 
Pilot Delphi Round (6 experts enrolled in the study) 
Actual Delphi Rounds (18 experts enrolled in the study) 
The Pilot Delphi Round  
The First Delphi Round 
Suitability of the presented items in assessing risks for DRPs in the aged ≥65 years 
Response rate 78% (14/18) 
Consensus reached for 36% (33/91) of the items 
11 new items suggested by the panelists, 1 item withdrawn, 1 item divided into two 
One panelist dropped out of the survey 
The Second Delphi Round 
Suitability of the presented items in assessing risks for DRPs in the aged ≥65 years 
Response rate 76% (13/17) 
Consensus reached for 22% (15/69) of the items 
The Third Delphi Round  
Importance of the items in the final DRP-RAT i.e., significance of each item as an 
indicator for predicting DRPs in the aged ≥65 years 
Response rate 94% (16/17) 
Final scores from 4±1.12 to 4.94±0.24 within range 5 (important) – 1 (unimportant) 
The final DRP Risk Assessment Tool 
Altogether 59 items (each component of multi-component items are counted as single 
items) 
o 48/102 (47%) items that reached consensus during the Delphi Rounds 
o 11 items included by the decision of the Research Group 
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9.3 Feasibility of the DRP-RAT among practical nurses (III)  
9.3.1 Quantitative data gathered from town B   
9.3.1.1 Time to complete the DRP-RAT and identification of the risk medicines 
PNs (n=25) in town B returned altogether 85 medication risk assessments conducted as post-
assignments by using DRP-RAT. Of those, 75 included a note of the time the PNs had spent in 
reviewing one client’s medication and 68 included a medication list. The time spent in reviewing one 
client’s medication using the DRP-RAT varied from 10 to 45 minutes (mean 20±8, n=75). The PNs 
had identified reliably most (96/109; 88%) of the risk medicines used by their clients (Table 18). 
Non-steroidal anti-inflammatory drugs (NSAIDs), theophylline and diuretics (combination products) 
were most problematic.  
Table 18. Reliability of the PNsʼ answers concerning risk medicines listed in the DRP-RAT 
Risk medicines listed in 
the DRP-RAT 
Users total 
n 
Recognized 
n (%) 
Not 
recognized 
n (%) 
Recognized 
false1) 
NSAIDs2)                          8 3 (38%) 5 (62%) 0 
Diuretics                          38 32 (84%) 6 (16%) 2 
Cholesterol lowering 
medicines 
25 24 (96%) 1 (4%) 3 
Amiodarone 0 0 (100%) 0 (0%) 1 
Carbamazepine 1 1 (100%) 0 (0%) 1 
Digoxin                           12 12 (100%) 0 (0%) 2 
Fluoxetine 1 1 (100%) 0 (0%) 1 
Lithium 0 0 (100%) 0 (0%) 2 
Methotrexate 0 0 (100%) 0 (0%) 0 
Theofylline 2 1 (50%) 1 (50%) 1 
Warfarin 22 22 (100%) 0 (0%) 0 
Total 109 96 (88%) 13 (12%) 13 
1) Recognized, although did not exist in client’s medication card/list 
2) Non-steroidal anti-inflammatory drugs  
9.3.2 Qualitative data gathered from towns A and B 
9.3.2.1 Utility of the DRP-RAT 
Response rate of the PN training feedback forms was 64% (23/36; Town A, n=8; Town B, n=15). Of 
the respondents (n=23), 43% reported that they felt it was easy or quite easy to answer the questions 
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of Tool. One fourth (26%) of the respondents reported having difficulties in recognizing generic 
medicines and, that most of the completing time of the DRP-RAT was spent in clarifying generic and 
trade names. Time constraints, home-care workers’ and/or clients’ lack of interest to client’s 
pharmacotherapy and short client contacts (i.e., several PNs visit the same client) were the most 
common barriers to use of the tool. Difficulties in identifying NSAIDs did not arise during the face-
to-face discussions nor in the feedback forms. Over a half of the respondents (61%) reported that the 
DRP-RAT would help in every-day work. One fourth (26%) reported that the Tool would possibly 
help them. Two PNs (9%) reported that the Tool would not help and one PN (4%) did not comment. 
The utility of the tool was also assessed through face-to-face discussions. The PNs had several 
suggestions how to use the Tool in their daily work but also at organization level (Table 19). They 
highlighted the importance of teamwork between all professions dealing with pharmacotherapy of 
the aged to ensure medication safety and thought that the DRP-RAT could serve as a communication 
aid between different professions. Increasing burden of the PNs making home visits arose several 
times during the face-to-face discussions. The PNs felt that they often are left alone with the problems 
of their increasingly old and multimorbid clients. The PNs had several suggestions to improve the 
tool. Based on those, two items were included in the next version of the DRP-RAT (used in study IV, 
Appendix): 1) questions about the client’s alcohol use (Audit C) and 2) a question: Is there anyone 
who determines whether the client takes his/her medicines?  
It also turned out that there were shortcomings in the medication management process, e.g., the 
PNs reported that they had no systematic way to detect and report potential ADRs, which were 
common among their aged clients. The PNs though that the tool would help them to notice and report 
the most important ADRs and other risks in pharmacotherapy.  
9.3.2.2 Overall feedback 
Two-thirds of the respondents (65%; n=15/23) to the feedback forms gave positive feedback about 
the DRP-RAT and the related training program. They responded that the training program was 
interesting and useful and that they learned a lot about geriatric pharmacotherapy during the program. 
Many PNs felt that their opinions were taken into account because of the interactivity of the workshop 
day. They commented that physicians should also be informed about the DRP-RAT. One third of the 
respondents (35%; n=8/23) did not comment indicating neutral feedback.  
9.3.2.3 Feedback to health care managers 
The content of the Tool and the interactivity of the training program enabled the PNs to recognize 
and discuss development needs in the medication management process in HC from their viewpoints. 
The need for 1) enhanced co-operation with client’s care givers and 2) creating a systematic way to 
monitor and deal with potential DRPs, especially the ADRs, were the most often mentioned 
development needs. In addition to the above mentioned items, PNsʼ educational needs concerning 
medicines (especially NSAIDs and generic names of medicines) were brought to the attention of 
health care managers in the feedback session. 
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Table 19. Practical nurses’ opinions about the utility of the DRP-RAT  
Practical nurses’ suggestions how to use the Tool  
The tool could serve as a communication aid: 
? An instrument for interprofessional teamwork (PN-nurse-physician-pharmacist) 
? Promotes co-operation with clientsʼ care givers 
The tool gives a reminder: 
? About the importance of things concerning medication safety 
? To take notice of the clientʼs total medication 
? To take more notice on monitoring and reporting possible ADRs e.g., when starting a 
new medicine 
? About the problems that maybe have existed, but have not been taken into action 
(things become concrete when they are written down) 
Could be used: 
? In the account of a new client 
? When making service and care plans1) 
? During preventive home visits2)  
? When clients are transferred between health care units 
? When educating new members of a HC team 
The Tool helps the PNs to be up-to-date concerning clients’ medicines, especially when the 
medicines are administered by someone else (e.g., automated dose dispensing3)) 
Abbreviations: ADR=Adverse Drug Reaction, PN=Practical Nurse  
1) In Finland, regular HC clients have a valid service and care plan (The Ministry of Social Affairs and Health 2008) 
The plan is based on an assessment of the client’s health status, functional capacity and help needs defined in co-
operation with the client (and/or clientʼs family or friends) and HC workers 
2) Legislative visits aiming to support wellbeing, health and functional capacity and to provide information about 
municipality's services for the elderly aiming to help older people to continue living at home (The Ministry of Social 
Affairs and Health 2008 and 2012) 
3) Medicines are packed in unit-dose bags according to administration times (Sinnemäki et al. 2013 and 2014)  
9.4 Reliability of the medication risk assessments conducted by PNs by 
using DRP-RAT and the clinically most significant DRPs needing action 
(IV) 
The PNs (n=26) returned a total of 46 completed DRP Risk Assessments including Audit C 
assessments for alcohol consumption (mean 1.8 assessments per PN). The mean age of the home-care 
clients whose medications the PNs reviewed (n=46), was 83 (range 64–96) years. Most of them (65%) 
were women and lived alone (91%). They had a mean of 9.5 (range 4–15) prescription drugs in regular 
use, mean 2.9 (range 0–12) as needed prescription drugs and mean 0.2 (range 0–1) prescription drugs 
taken as a course. Twelve clients (26%) had used Over-the-Counter (OTC)-medications for two 
weeks prior to the risk assessment.  
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9.4.1 The Toolʼs ability to assist in identifying older HC clients at risk of clinically 
significant DRPs 
Of the 46 clients, the geriatrician reviewed altogether 45 clients’ medications using all three methods 
(one client was excluded as he regularly visited a specialist and tertiary care university hospital). 
Figure 16 shows the results of the medication reviews. Compared to the “gold standard” (Method 2), 
Method 1 resulted in a false negative rating in 7% (95% CI 1.4–18.3) of the cases (3/45). Using 
Method 2, the additional data from the health centreʼs medical records (blood pressure, weight loss, 
laboratory values) resulted in positive ratings concerning these three cases. The time the geriatrician 
spent reviewing one client’s medicines, using the Tool, varied from 2 to 6 minutes (mean 3.9).  
 
 
Figure 16 “At-risk patients” and “not at-risk patients” resulting from three different medication review 
methods applied by the geriatrician. 1=DRP-RAT and medication list, 2=Health centre’s 
medication records (“gold standard”), 3=Methods 1 and 2 together 
9.4.2 Validity of PNsʼ recommendations for intervening actions 
The PNs had completed the section recommendations for action to resolve potential DRPs in 39 out 
of 45 (87%) DRP-RATs. A comprehensive medication review was the most commonly recommended 
action (27/39), followed by automated dose dispensing service (19/39). The geriatrician appraised the 
recommendations valid in 82% of the cases (32/39).  
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9.4.3 DRP-RATʼs ability to provide clinically important timely patient information for 
clinical decision making 
The geriatrician reported that 87% (39/45) of the medication risk assessments completed by PNs 
using DRP-RAT provided her with clinically important timely patient information for clinical 
decision making. Four (9%) of the risk assessments provided some and two (4%) no additional 
clinically important information. 
In 71% (n=32) of the risk assessments the Tool provided the geriatrician with valuable information 
about symptoms suggestive of ADRs. PNsʼ notes about medicines prescribed by private practitioners, 
medicines that clients had not taken although prescribed, and use of herbal products also clarified the 
client’s medication use to the geriatrician. Other important information for clinical decision making 
were related to the caregiver’s concern about the client’s medication use, and information about the 
client’s alcohol consumption and adherence.  
The geriatrician perceived as a deficiency in the medication risk assessment by DRP-RAT that 
the Tool lacked information about the patientʼs health status (e.g., current blood pressure, heart rate, 
weight, weight changes, bowel motion). However, her experience-based opinion was that the PN-
completed Tool, even in its current form without information on client’s health status, assisted the 
physician to focus on the most important DRPs (including the suggested ADRs), i.e., to prepare better 
for more comprehensive medication reviews.  
9.4.4 Prevalence and clinical significance of the risk predicting factors included in 
DRP-RAT 
Most of the risk predicting factors listed in the Tool were prevalent among the study sample, the 
prevalence varying from 2–91% (IV: Table 3). Over half (60%; n=12) of the risk predicting factors 
exceeded the prevalence of 20%. 
The clinically most significant risk factors for DRPs that the geriatrician prioritized are presented 
in Table 20. She classified symptoms suggestive of ADRs as the most important indicator for 
clinically significant DRPs and thus, a reason to conduct a more comprehensive medication review. 
Among the most significant risk factors were also visiting several practitioners, having more than one 
fall in the past 12 months prior to the DRP risk assessment and using “high-risk” medicines. Factors 
related to poor adherence were classified as risk factors in 25% (n=11) of the HC clients. In this study, 
the number of medicines and the number of medication doses taken were not classified among the 
most important risk predicting factors (Table 20).  
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Table 20. The most important risk predicting factors for DRPs as identified by the geriatrician and 
their prevalence in the study population  
Risk predicting factor 
(n=number of PNsʼ notes (yes or no) on a risk 
predicting item)  
Prevalence 
of the risk 
predicting 
factors 
reported 
by PNs  
 
(n; % of the 
cases) 
Importance of the 
questions in 
identifying risks for 
clinically significant 
DRPs conformed by 
the geriatrician  
(n=number of times the 
geriatrician evaluated 
the risk predicting 
factor as a reason for 
risk; % of the cases)  
Has the client had any of the following symptoms in the 
last 4 weeks? drowsiness, fatigue, skin rash or itch, 
dizziness, urination problems, muscle pains, nausea, 
diarrhea, constipation, dizziness when getting up, 
recurrent falls, swellings, memory problems, confusion,  
visual problems, stiffness, troubles in walking, low blood 
pressure; systolic pressure under 110 mmHg (n=44) 
40 (yes) 
(91%) 
26 
(65%) 
 
Does the client have more than one physician 
involved in his/her care? (e.g., general practitioners, 
specialists, private practitioners) (n=44) 
22 (yes) 
(50%) 
20 
(91%) 
 
Has the client had more than one fall in the past 12 
months? (n=44) 
18 (yes) 
(41%) 
18 
(100%) 
Does the client use any of the following medicines 
(please check the ones used)? amiodarone, 
carbamazepine, digoxin, fluoxetine, lithium,  
methotrexate, theophylline, warfarin (n=44) 
16 (yes) 
(36%) 
14 
(88%) 
 
Has the client had troubles in a) remembering to take the 
medicines? b) following the medicines regimen? c) 
knowing what his or her medicines are used for? d) 
affording the medicines (i.e., economic problems)? e) 
opening the drug bottles or packages or managing with 
medicines related therapeutic devices? (n=44) 
30 (yes) 
(68%) 
11 
(37%) 
 
Does the client use medicines that a) relieve pain by 
reducing inflammation (does not apply to paracetamol)? 
b) elevate the rate of urination (diuretics)?  c) are 
intended to lower the cholesterol level (statins)?) d) the 
physician does not know about? (n=44) 
35 (yes) 
(80%) 
8 
(23%) 
 
Have the client's relatives/proxies expressed their 
concern about the client's medicine use? (n=43) 
7 (yes) 
(16%) 
7 
(100%) 
Has the client started a new medicine in the last 4 
weeks? (excluding different brands of the same active 
incredient) (n=44) 
7 (yes) 
(16%) 
6 
(86%) 
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9.4.5 DRPs in the study sample documented by the geriatrician and drugs or drug 
groups involved in them  
9.4.5.1 Drug-related problems and their causes  
Using the “gold standard” i.e., Medication Review Method 2 the geriatrician identified altogether 139 
potential DRPs (an average of 3.1 per patient, range 1–8). 
Over half (53 %; n= 73/139) of the identified DRPs were related to potential adverse reactions 
(i.e., patient suffers, or will possibly suffer, from an adverse drug event), 34%; n=47/139 were related 
to treatment effectiveness, i.e., there is a (potential) problem with the (lack of) effect of the 
pharmacotherapy; and the rest (14%; n=19/139) were related to treatment costs (i.e., the drug 
treatment is more costly than necessary). 
The potential causes of DRPs are presented in Table 21. Two-thirds of the causes (69%; n=96/139) 
were related to drug selection, 16% (22/139) to treatment duration, 14% (19/139) to dose selection 
and 1% (2/139) to drug form. Drug groups most commonly involved in these DRPs were drugs for 
cardiovascular diseases (n=20), hypnotics and sedatives (n=13), drugs for osteoporosis (n=13), 
Selective Serotonin Reuptake Inhibitors (SSRIs) (n=11) and drugs used for diabetes (n=8).  
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10 Discussion 
10.1 DRP-RAT (I–IV) 
This dissertation indicates that the DRP-RAT, developed and validated in this PhD study (I–IV), 
could make it possible to more effectively involve PNs working in HC in medication risk management 
among home-dwelling aged. Unlike existing nurse-administered risk assessment tools focusing 
mainly on issues relating to adherence and medication management, the DRP-RAT focuses on the 
highest priority risks related to the pharmacological effects of the medications but also on factors 
related to the medication use process. In addition to identifying pharmacotherapeutic risks, the DRP-
RAT assists in finding solutions to these problems, which also is a unique feature when the Tool is 
compared to previous risk assessment tools (Johnson et al. 2005, Pit et al. 2008, Fuller and Watson 
2015, Gusdal et al. 2011).  
Although PNs are those who most often visit aged HC patients they are ignored from interventions 
to improve medication safety among the aged both at international (Chapter 4) and national level 
(Chapters 5 and 6). This PhD study is unique as it aims to involve also the PNs in medication risk 
management.  
This dissertation revealed several improvement needs at systems level in HC organization but also 
PNsʼ educational needs related to geriatric pharmacotherapy (III). The study also brought up new 
information about the highest priority risks that should be focused on in geriatric pharmacotherapy 
(IV). These risks are related both to pharmacological effects of medication and to medication use 
process.  
10.2 Development of the draft DRP-RAT (I, unpublished) 
To ensure a comprehensive content of draft DRP-RAT two systematic literature reviews were 
conducted (I, Dimitrow et al. 2013, unpublished). The first systematic review about existing criteria 
measuring inappropriate prescribing among the aged brought out that majority of the existing explicit 
criteria are consensus validated and based on Beers criteria and their updates (I). It may be discussed 
if this feature is a shortcoming or an advantage. Lack of new innovation may be missing; the 
development methods (i.e., consensus methods) and structure and contents of other criteria are quite 
similar to the Beers criteria, although the drug selection has been modified according to the 
developing countryʼs drug selection. However, certain basic items originating from Beers criteria 
have been proved valid through several consensus panels all over the world offering, to some extent, 
transnational comparability of the process. This may be considered as an advantage.  
Each of the reviewed criteria has limitations. The contents of the criteria may be limited as a 
consequence of the development method. Because of the nature of the Delphi technique (Dalkey and 
Helmer 1963, Campbell and Cantrill 2001) important items may be dropped if the panelists cannot 
reach consensus (Fick et al. 2003). The contents of the criteria may also be limited as a consequence 
of the purpose of the development.  
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Through time explicit criteria have evolved more comprehensive and thus, their use requires more 
clinical patient data (Beers 1991, AGS 2015). This reflects the growing knowledge about this research 
area and thus, growing understanding that applying the criteria in clinical work always require 
individual clinical judgement. Although the criteria measuring inappropriate prescribing are 
extremely important they mainly measure the “pharmacological appropriateness on prescribing” and 
thus, target only a small part of the whole problem (Budnitz et al. 2011). However, DRPs may occur 
during the whole medication use process (Cipolle et al. 2004, PCNE 2010, Basger et al. 2015). Thus, 
to complement the first literature review, another systematic review searching existing geriatric 
specific tools designed to screen aged patients at risk of DRPs was conducted (unpublished, Chapter 
4.2.3). The second literature review brought evidence based information and a systems approach to 
risk assessment. In addition, the research group’s clinical experience was utilized in the development 
of the draft DRP-RAT. Combining the results of these two literature reviews complemented with 
clinical expertise of the research group assured comprehensive content of the draft DRP-RAT.  
10.3 Content validation of the draft DRP-RAT (II) 
Developing the draft DRP-RAT followed a rigorously selective process to produce an instrument that 
could be used by PNs supporting medication management for home-dwelling clients ≥65 years but 
who have only modest formal training in pharmacotherapy. A three-round Delphi process yielded 
consensus (≥80 % agreement on an item) on 48 DRP risk assessment items and a final agreement on 
the resulting 59-item tool.  
In addition to indicating potential risks from the pharmacological effects of the medications, 
particularly ADRs, the DRP-RAT includes measures on risks related to poor adherence and to poor 
medication management, such as not involving clients and/or their caregivers in care, infrequent 
follow-ups, and poor coordination of care among the client’s health care providers. The importance 
of adherence and medication management for minimizing DRP risks was confirmed by the Delphi 
panel experts who gave their final highest importance ratings to items indicating whether the client 
has a timely medication card/list and whether the client adheres to his/her medication. These 
indicators, either one or both, are missing or have had a minor role in previous tools that assess DRP 
risks in the aged (Barenholz Levy 2003, Fuller and Watson 2005, Johnson et al. 2005, Gusdal et al. 
2011). Another unique feature of the final DRP-RAT is that, in addition to assisting PNs in identifying 
home-dwelling aged clients who have or who are at risk for DRPs that require actions, the tool 
actually guides the selection of such actions. This feature of the tool may increase awareness among 
PNs and also the aged of options to improve medication safety (e.g., CMR, dose dispensing, 
consulting an accredited pharmacist). 
One third of the individual items in the DRP-RAT that resulted from the Delphi survey are 
indicators of potentially harmful ADRs. The number of the ADRs is high, even though over half of 
the initially nominated ADRs (28/46, 61 %) and most of the initially suggested problematic medicines 
(14/18, 78 %) were excluded during the successive Delphi rounds. This indicates the importance of 
taking ADRs into account as an integral part of medication use and of identifying ways to identify 
them early and manage them. The DRP-RAT explicitly guides PNs in the detection of specific 
symptoms associated with potential ADRs requiring attention. Otherwise, ADRs tend to be 
underreported among the aged as they may consider the symptoms to be a part of normal aging 
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(Lampela et al. 2007). It is notable that the list of indicators of potential ADRs covers symptoms that 
may be caused by PIMs but also symptoms that may be caused by other medicines typically used by 
aged medicine users i.e., hypoglycemics, blood pressure medications, diuretics. This is a very 
important feature of the tool, as it is well documented in literature, that few commonly used 
medications (e.g., warfarin, hypoglycemics) represent as a leading cause of emergency department 
visits and hospitalizations in the aged (Budnitz et al. 2011). PIMs were implicated only in 1.2% of 
hospitalizations. 
Expert panelists reached consensus on 48 of 102 initial items (47%), which is less than the ratio 
in several other conceptually similar Delphi surveys reported in the health services’ research literature 
(Cantrill et al. 1998, Morris and Cantrill 2003, Rognstad et al. 2009). The criterion for consensus 
(80%) to determine attainment of the goal was high (Diamond et al. 2014): consequently, 
achievement of consensus was low. Therefore, only the most important items for identifying DRP 
risks in home-dwelling clients ≥65 years were retained in the final DRP-RAT. Furthermore, our 
Delphi panel comprised physicians, pharmacists, and nurses who are leading experts in geriatric care 
and pharmacotherapy in Finland. Thus, they should have had the most comprehensive knowledge of 
typical potentially harmful ADRs and other risks for DRPs which require active management. In 
order to keep the panelists focused on the DRP-RAT’s intended use, it was stressed to them before 
each Delphi round that the tool was meant to be administered by PNs and they have to consider a 
PN’s ability to evaluate DRP risks for their individual home-dwelling aged clients. 
One of the Delphi technique’s limitations is that important items may be excluded if the panelists 
cannot reach consensus (Fick et al. 2003). To avoid such omissions, we retained 11 items in the final 
DRP-RAT despite their lacking consensus. Based on scientific evidence and our research group’s 
clinical expertise, those items were considered too important for the intended purpose to be excluded. 
Also, the Delphi panelists rated these retained items as important or moderately important during the 
third round survey, indicating their endorsement for including these additional 11 items in the final 
DRP-RAT. 
10.4 Assessing the feasibility of the content validated DRP-RAT among 
PNs (III) 
The results indicate that the DRP-RAT is feasible for the PNs and suitable for their skills. The brief 
training on the content and use of the tool seems to be sufficient for ensuring reliable use of the tool. 
HC is teamwork between physicians, nurses and PNs. However, they often are separated from 
each other as they work to care for the client, the PNs being those who most often visit the client. The 
PNs felt that they often are left alone with the clients and their pharmacotherapy problems. Thus, they 
thought that a structured Tool would help them to contact the doctor in acute difficult situations. They 
also found the Tool to be a useful communication aid to help them to collect and report essential data 
about the client’s pharmacotherapy risks to be discussed with other members of the interdisciplinary 
HC team (physicians, nurses, PNs). The PNs especially stressed the importance of the Tool’s 
questions assessing symptoms suggestive for ADRs. The structured Tool would also harmonize the 
information given by several PNs with different communication skills. Previous studies support their 
opinion; it has been proved that a structured method of communication improves the clarity and 
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content of interprofessional communication in nursing homes and has the potential to improve nurse 
and physician work satisfaction (Renz et al. 2013). 
10.4.1 Problems that the PNs met when reviewing medications using the DRP-RAT 
The DRP-RAT is designed to indicate potential risks from the pharmacological effects of the 
medications and it also includes measures on risks related to medication management process. Thus, 
the problems that the PNs met when using the Tool were related to their own skills as well as to the 
system. 
The time scale (10–45 minutes) was wide in completing the Tool as a post-assignment, which 
may indicate a variation in the skills of the PNs but also a variation in clients’ health and complexity 
of medications. The PNs reported that most of the time required to complete the Tool as a pre-
assignment (10–60 minutes, median 30, mean 27±12) was spent in clarifying generic and trade names 
of medicines. One quarter of PNs reported still having difficulties with generic names when 
completing the post-assignments although the completing time was shortened significantly (10–45 
minutes, median 20, mean 20±8). This indicates that if the Tool is in regular use the completing time 
may shorten. 
Almost half of the PNs reported that they had difficulties with generic names of medicines as they 
were used to communicating with trade names. Although generic substitution saves both the patients’ 
and society’s medicine expenditures, several studies indicate that generic substitution is a risk factor 
for medication errors, e.g., overdosing (Schwab et al. 2002, Håkonsen et al. 2011, Lobo et al. 2013). 
In addition, all the extra time spent in clarifying generic names of medicines is subtracted from caring 
the client. The lack of knowledge concerning risk medicines, especially NSAIDs, is also an issue that 
must be taken into account when developing continuing education and PN curricula. More focus on 
NSAIDs must be paid in future trainigs about the purpose and use of the DRP-RAT. 
The other problems that the PNs met when using the Tool related more to the HC system than to 
the skills of the PNs (e.g., short duration of home visits and client contacts, items concerning other 
care givers and difficulties in knowing about the client’s visits to private physicians).  
10.5 Validation of the DRP-RAT in clinical practice (IV)  
This study indicated that in most cases PNs were able to find those patients at high risk for clinically 
significant DRPs by using DRP-RAT. Thus, the Tool can be used in screening aged patients at risk 
for DRPs, and it provides clinically significant information for physician’s decision making. The 
study also provided evidence on the highest priority risks that need action in geriatric 
pharmacotherapy.  
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10.5.1 ADRs as the highest priority risks for DRPs  
This study brought some new information about the clinical importance of different risk factors for 
DRPs. The geriatrician reported that the most important patient information provided by the Tool was 
timely identification of symptoms suggestive of ADRs. She also classified the documented symptoms 
suggestive of ADRs as the most important risk factors for DRPs. The clinical importance of ADRs 
has been found also in several previous studies. Actually, ADRs have been recognized as the most 
common type of DRPs to result in severe harm jeopardizing patient safety (Pirmohamed et al. 2004, 
Patel et al. 2007, van der Hooft et al. 2008, Pedrós et al. 2016). However, in aged patients, the majority 
(40%–70%) of ADRs are judged to be preventable (Pirmohamed et al. 2004, Patel et al. 2007, van 
der Hooft et al. 2008) and thus, identification and early detection of ARDs are critically important 
(Davies and O'Mahony 2015). Involving more than one physician in patient’s care, having more than 
one fall during the year prior the risk assessment, using high risk medicines, nonadherence and 
client’s relative’s/proxyʼs concern about the client’s medicine use were also among the most 
important indicators of risk for DRPs.  
Unlike several other studies, this study did not find the number of medicines or the number of 
daily doses to be among the most significant risk factors. Fulton and Allen reported that the risk of 
ADR is 13% when using two medications, increasing up to 58 % when using five medications (Fulton 
and Allen 2005). When using seven or more medications the incidence of ADRs increases to 82% 
(Prybus 2002). Several risk managing studies also list the number of medicines and/or number of 
daily doses as an important risk factor for DRPs (Koechler et al. 1989, Barenholz Levy 2003, Field 
et al. 2004, Fuller and Watson 2005, Johnson et al. 2005). One explanation for the differing result 
may be that the listed symptoms suggestive of ADRs are much stronger indicators as they measure 
the unwanted outcome of inappropriate prescribing or medicine use. It has also been stated that 
polypharmacy is not a problem if effectively managed. However, this cannot be considered as an 
explanation in this study as the patients had several DRPs. As a result of a strict validation process of 
the items included in DRP-RAT (I–III), all items are indicators for high risk of DRPs and thus, this 
study picked out the most significant risk predicting indicators which should be prioritized in 
medication risk management of the aged. The information about the most significant risk predicting 
indicators produced by this study may be useful when defining target groups for medication reviews. 
However, the finding about the risk predicting factors base on small population and thus, should be 
investigated more in detail with larger number of patients (Jirón et al. 2016).  
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10.6 Strengths and limitations of the study 
10.6.1 Development and content validation of the DRP-RAT (I, II) 
10.6.1.1 Literature searches (I) 
Both literature searches conform to the PRISMA checklist (Moher et al. 2009). Together, the two 
literature searches cover risks related to the pharmacological effects of the medications but also risks 
related to the medicine use process and thus, enabled a comprehensive approach to risk management 
when developing the draft Tool. The unpublished literature search coved all relevant databases, such 
as Evidence Based Medicine Database, Web of Knowledge, Scopus and Cinahl which may be 
considered as a strength of this study. Restricting the first systematic search (I) to only two databases 
(MEDLINE and PubMed) may have limited the results of this study. We updated the first literature 
review in 2012, covering published studies until June 2012 (Dimitrow et al. 2013). Thus, our literature 
has a comprehensive coverage of potentially inappropriate medicines and medicine classes and is still 
quite well up-to-date, including, e.g., the update of the Beers criteria in 2012 (AGS 2012), but not the 
latest update in 2015 (AGS 2015). Also the EU(7)-PIM list is missing (Renom-Guiteras et al. 2015).  
The search terms in both searches may have been insufficient. However, the searches were 
augmented with a manual search complementing the original search. As we only searched English 
language articles, criteria published in other languages were missed. Concerning the first literature 
search; most explicit criteria based on Beers criteria or their updates may have produced bias across 
the criteria, and thus, possible false conclusions and deficiencies may have remained throughout the 
criteria. This may introduce bias in the results of the first systematic review.  
 10.6.1.2 Delphi survey (II) 
A Delphi survey’s success depends on the selection criteria, process, and quality of the expert panel 
(Campbell and Cantrill 2001, Boulkedid et al. 2011, Diamond et al. 2014). To ensure a broad 
representation of skills and competence in geriatric care and pharmacotherapy, we invited panelists 
from three relevant but different expert professional groups: physicians, nurses, and pharmacists. 
Conducting the survey online facilitated broad geographic representation of that expertise. As the 
panelists were carefully selected from among the best experts in geriatric care and pharmacotherapy 
in Finland, we believe they had a comprehensive understanding for validating the content of the DRP-
RAT. It may be considered a limitation that the expert panel did not include PNs although they were 
the designated end users of the DRP-RAT. The decision not to include PNs in the expert panel is 
justified as we wanted to have the best available expertise to validate the content of the tool. However, 
the structure of the draft DRP-RAT was developed taking in to account PNsʼ skills. Subsequently, 
PNs were strongly involved in the next steps (III, IV) of the validation process.  
A multiprofessional 13–16-member expert panel responded in the three Delphi rounds. This is 
consistent with the panel size in several other Delphi surveys (Boulkedid et al. 2011). Thus, we 
believe that the number of participants is high enough to provide confidence in the stability of the 
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results. Response rates in the Delphi rounds in the current study varied from 76 to 94%, indicating 
the panelists’ involvement and commitment to the development of the DRP-RAT. The strength of 
this study is also that we have reported response rates for all rounds, feedback was given between 
rounds, and we had the same criterion of consensus (80%) through all Delphi rounds which has not 
been self-evident in several other Delphi studies (Boulkedid et al. 2011).  
Even though the draft DRP-RAT was initially based on two systematic literature reviews (I, 
Dimitrow et al. 2013, unpublished), the draft tool may have missed some relevant aspects of patient 
care. That is why the expert panelists were asked to suggest additional items based on their clinical 
expertise. We also drew on the research group’s special expertise in geriatric pharmacotherapy and 
geriatrics to complement the evidence based origins for items in the final DRP-RAT. Thus, we believe 
that the development and validation processes have been rigorous enough to overcome potential 
deficiencies with the methodology.  
10.6.2 Assessing the feasibility of the DRP-RAT among PNs and validation of the 
Tool in clinical practice (III, IV) 
Triangulation was used in both studies when collecting the data. This research method consists of 
different types of approach (i.e., collecting both qualitative and quantitative data) and is the strength 
of this study, as it offers a wider approach in evaluating the validity of the DRP-RAT.  
The small sample size in both studies (III; PNs n=36, IV; PNs n=26, patients n=46) may have 
limited the generalizability of the results. However, concerning study III, conducting the study in HC 
teams of two towns both having their own routines and practices in providing pharmacotherapy in 
PNsʼ normal working environment supports the validity of the results. Selection of PNs who 
participated in the training may have caused bias (participation was voluntary, not all PNs 
participated). It may also be a limitation that only one of the researchers made notes on the interactive 
discussions during both workshop days. This may have led the note-taker’s individual views to impact 
on the notes. 
The major limitations in study IV are a small sample size and the fact that the same geriatrician 
did all the medication reviews regardless of their comprehensiveness. When conducting the reviews 
using three different Medication Review Methods the geriatrician was instructed to be “blind” to her 
previous reviews for the same patient. How much the previous reviews finally affected on the next 
ones remains unknown. To reduce bias the order of the three medication review methods was 
carefully considered and the following order was applied: 1) based on DRP-RAT with medication 
list, 2) based on health centre’s medical records and 3) based on methods 1 and 2 together.  
According to the “gold standard” i.e., Medication Review Method 2, all patients were classified 
as “at-risk patients”, which can be considered as a weakness of this study. Because of this result we 
were not able to compare “the at-risk patients” with “not at-risk patients” and the resolution power of 
the three Medication Review Methods used. To extrapolate the results of this study, future studies 
with larger number of patients and with more than one geriatrician are needed.  
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10.7 Future studies 
The DRP-RAT is developed for PNs working in HC. However, it would be worth testing the Tool or 
parts of it i.e., the most important risk predicting factors, also in other settings, such as community 
pharmacies to identify risk patients but also to support medication reviews. In addition to community 
pharmacists, future studies may also engage clinical medication review pharmacists in medication 
risk management using the DRP-RAT. Also a patient or proxy administered version of the DRP-RAT 
would be worth developing and testing. A scoring system based on the importance of the items would 
help interpretation of the Tool. In Finland, we currently do not have clear target groups for medication 
review services (Chapter 4.2.1). The information about the most significant risk predicting indicators 
produced by this study may be useful when defining target groups for medication reviews. It would 
be worth testing to integrate the DRP-RAT in software programs to be used in mobile devices and as 
a part of a comprehensive geriatric assessment (CGA). 
The PNs were delivered concrete applied pharmacotherapy education that could be implemented 
directly to their own work as well as to unit’s medication management process. This kind of training 
related to pharmacotherapy risk management should be delivered more as continuing education. 
Future studies are needed to investigate the utility of integrating the training on the content and use 
of the DRP-RAT into PN curricula. Increasing knowledge about risks in geriatric pharmacotherapy 
sets a demand to update the DRP-RAT. Future studies are also needed to evaluate the effects of PNsʼ 
risk assessments using the DRP-RAT on clinical, humanistic and economic outcomes.  
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11 Conclusions 
This PhD study indicates that the DRP-RAT, developed and validated in this study, could make it 
possible to more effectively involve PNs working in HC in medication risk management among 
home-dwelling aged, and that medication risk management should be focused on the highest priority 
risks. Unlike existing nurse-administered risk assessment tools focusing mainly on issues relating to 
adherence and medication management, the DRP-RAT focuses on the highest priority risks related 
to the pharmacological effects of the medications but also on factors related to the medication use 
process. Integrating a training to use the DRP-RAT into PN curricula is important. Future studies are 
needed to evaluate the implementation of the Tool in clinical practice and the effects of PNsʼ more 
systematic risk assessments using the DRP-RAT on clinical, humanistic and economic outcomes of 
geriatric pharmacotherapy. 
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Appendix 
The Drug-Related Problem Risk Assessment Tool (DRP-RAT) (I: Table 1) 
1) Basic Client Data 
Name 
Identity number 
Age:         years 
Gender:  male           female                       
Does the client live alone? 
Does the client have an up-to-date medication card/list? 
Who administers the client’s medicines? 
Is there anyone who determines whether the client takes his/her medicines?a) 
2) Potential Risks for DRPs in Medication Use (“yes” or “no" answering options or select an 
appropriate item(s)) 
1. Does the client have sevenb) or more prescription medicines in curent regular use? (excluding basic 
creams) 
2. Does the client take 12 or more medicine doses regularly each day (excluding basic creams)? 
Example of counting the doses: Drug 1: 1 tablet 3 times a day = 3 doses, Drug 2: 1 dose 2 times a 
day=2 doses, i.e., in total 5 doses a day 
3. Is the client currently taking medicines for three or more diseases or symptoms? (including acute 
diseases) 
4. Has the client started a new medicine in the last 4 weeks? (excluding different brands of the same 
active ingredient) 
5. Does the client use medicines that; a) relieve pain by reducing inflammation (does not apply to 
paracetamol)? b) elevate the rate of urination (diuretics)?b) c) are intended to lower the cholesterol 
level (statins)b)?  d) the physician does not know about? 
6. Does the client use any of the folowing medicines (please check the ones used)? (the list contains 
medicines with a narrow therapeutic index, medicines for which regular monitoring would be 
necessary and medicines that otherwise are problematic for the aged) amiodaroneb), carbamazepine, 
digoxin, fluoxetine, lithium b), methotrexate b), theophyline b), warfarin 
7. Has the client used over-the-counter (OTC) medicines or vitamin, mineral or herbal products in the 
past two weeks? State which ones 
8. Has the client had any of the folowing symptoms in the last 4 weeks? (Please tick below ‘yes’ if it 
has been ongoing and add another tick in the right column, if the symptom is a new one = a 
symptom that had first occurred within the last 4 weeks), drowsiness, fatigue, skin rash or itch, 
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dizziness, urination problems, muscle pains, nausea. diarrhea, constipation, dizziness when getting 
up, recurrent falls, swellings, memory problems, confusion, visual problems, stiffness, troubles in 
walking, low blood pressure; systolic pressure under 110 mmHg b) 
9. Has the client had more than one fall in the past 12 months? 
10. Has the client/relative/visitor noticed any changes in client’s condition that could indicate adverse 
drug reactions related to changes in medicines regimen? 
3) Characteristics of the Client’s Care and Adherence (“yes” or “no" answering options or 
select an appropriate item(s)) 
a) Health, health care setting and care taking physician 
11. Does the client have three or more chronic diseases? 
12. Has the client been in short term care (e.g., interval care) in hospital, nursing home, sheltered 
housing, health centre ward or some other institution in the past 4 weeks? 
13. Does the client have more than one physician involved in his/her care? (e.g., general practitioners, 
specialists, private practitioners) 
b) Adherence  
14. Has the client had troubles in; a) remembering to take the medicines? b) following the medicines 
regimen? c) knowing what his or her medicines are used for? d) affording the medicines (i.e., 
economic problems)? e) opening the drug bottles or packages or managing with medicines related 
therapeutic devices? 
15. Does the client consciously sometimes take medicines differently than prescribed? 
16. Is the client (or his/her caregiver) aware of the client's diseases and their treatments? 
17. Is the client (or his/her caregiver administering the medication) aware of the medicines that the client 
uses? 
18. Have the client's relatives/proxies expressed their concern about the client's medicine use? 
4) Recommendations for Actions to Resolve DRPs (several items can be selected if 
necessary): 
a) Comprehensive Medication Review, b) Using dose dispensing device, c) Automated dose dispensing 
b), d) Visiting the personal physician, e) Visiting a diabetes or asthma nurse in the health centre, or the 
diabetes or asthma pharmacist in the pharmacy b), f) Weekly control visits by a home care nurse, g) 
Follow-up of the client’s condition (repeating the risk test) b) 
Client’s permission for possible intervening actions? 
A short questionnaire about the clientʼs alcohol consumption AUDIT C a) (Bush et al. 1998, Babor et 
al. 2001)  
a) Included in DRP-RAT based on study III 
b)Retained in the DRP-RAT by judgement of the research group (II) 
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